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ABSTRACT
Until recently, the main mechanism of argininosuccinate synthase (AS) regulation
was described to exist mainly at the level of transcription. Transcriptional regulation of
AS has been shown to be coordinate with eNOS in response to shear stress, hypoxia,
tumor necrosis factor α (TNF-α), and PPAR γ agonist troglitizone. However, it is now
understood that one level of NO regulation is cellular control of arginine availability to
eNOS via post-translational modifications of AS such as phosphorylation. The purpose of
this investigation was to determine under what conditions AS is phosphorylated at S328,
identify the pathway that AS phosphorylation at S328 plays a role, and how
phosphorylation affects AS function in endothelial cells. We developed a phosphospecific antibody directed against pS328 AS and assayed for increases or decreases in
phosphorylation relative to physiological factors. We found that AS phosphorylation at
S328 occurred when endothelial cells were stimulated with physiological factors that
stimulate nitric oxide production through calcium-dependent stimulation of eNOS.
Furthermore, by utilizing kinase inhibitors and kinase knockdown experiments, we
showed that phosphorylation at S328 significantly decreased when PKCα was knocked
down, suggesting that S328 phosphorylation of AS is involved in PKCα signaling. In
addition, by confocal microscopy, immunoprecipitation, and membrane fractionation, we
showed that phosphorylation at S328 of AS promotes its co-localization with eNOS in
the perinuclear region. These findings describe a novel pathway involving AS regulation

xi

of nitric oxide production, and may serve as a novel drug target in the restoration of
vascular nitric oxide homeostasis.

xii

INTRODUCTION
Function of vascular endothelium
Until the mid 1970s, the vascular endothelium was thought to mainly act as a
barrier to partition the lumen from other constituents of the vessel (1). Since
cardiovascular disease has been the most common cause of death in the US for several
decades (2), much research has been conducted to further investigate the role
endothelium plays in vascular biology. It is now understood that the endothelium is a
critical component of the vasculature in that it mediates multiple functions required for
cardiovascular homeostasis. For example, endothelial regulated permeability allows the
transmission of serum derived proteins (2) and via the transcellular pathway, and
leukocytes (2) mainly via the paracellular pathway, to reach the underlying tissue. More
recently, it has been established that leukocytes traverse the endothelium in a
transcellular manner as well (2). In normal, non-inflamed vessels, the transcellular
passage of plasma solutes and fluids, often mediated through endothelial caveolae, supply
tissues with essential nutrients that enable cell signaling and survival(3). The paracellular
pathway that usually mediates large protein and leukocyte transport at endothelial tight
junctions mediates the delivery of immune cells to reach remote sites of inflammation
upon tissue injury (4). However, in the event of vascular injury such as postischemic
reperfusion, endothelial permeability is increased (5). This is commonly referred to as
“leakage” and leads to tissue edema, thus impairing capillary flow and tissue gas
1

exchange (6). In addition, vascular injury can promote increased expression of
endothelial adhesion molecules allowing excessive monocyte adhesion and infiltration to
the vessel wall with subsequent atheroma formation (7).

In addition to solute and leukocyte transport, a critical role of the endothelium is
to generate signaling factors that alter vasodilation and vasoconstriction of the vessel.
Physiological factors produced by endothelial cells that lead to vasoconstriction include
endothelin-1, angiotensin II, and reactive oxygen species (ROS) (8, 9). Relating to
vasodilation, the primary molecular messenger responsible for decreasing vascular tone is
the free radical nitric oxide (NO) (10). NO is highly reactive and cannot be stored,
therefore its production requires a proximal relationship to its target (11). As a result, the
concentration of NO is inversely proportional to the distance it travels from the site of
production (12). Since NO is readily diffusible across plasma membranes, the production
of NO affects SMC relaxation after it is produced by the endothelium. The molecular
mechanism of NO mediated vasodilation requires the association of SMC soluble
guanylyl cyclase (sGC) with endothelial NO to convert GTP to cyclic GMP (cGMP) (13).
Protein kinase G activation occurs upon generation of cGMP and subsequently promotes
efflux of calcium from SMCs, leading to contraction inhibition (13). In the absence of
NO production, SMCs are in a hyper-constricted state that contributes to increased blood
pressure or hypertension (14).
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Because endothelial NO production is so vital to the regulation of vasodilation,
platelet aggregation, and leukocyte adhesion, endothelial dysfunction is defined by the
reduced capacity to generate NO (15). Consequently, endothelial dysfunction is often the
initial event in the atherosclerotic lesion cascade that ultimately leads to hypertension and
vessel occlusion (16). A heme containing homodimer called endothelial nitric oxide
synthase (eNOS) is responsible for catalyzing the conversion of arginine to citrulline and
NO in endothelial cells (Reaction 1) (17).
2 L-arginine + 3 NADPH + 3 H+ + 4 O2  2 citrulline + 2 nitric oxide + 3 NADP+ + 4 H2O (R1)

Control of NO production occurs through the direct interaction of eNOS with
caveolin-1 or the activated calcium sensor protein calmodulin (CaM). eNOS is held in an
inactive state when bound to caveolin and (18), upon interaction with activated CaM, is
subsequently displaced from caveolin. Interaction of eNOS with calmodulin promotes a
conformational change in the eNOS homodimer that allows the electron flux required for
NO production to occur (19). A number of mechanisms relating to dysregulation of
eNOS catalysis can ultimately lead to endothelial dysfunction (20).

Molecular mechanisms leading to endothelial dysfunction
Since impaired NO generation plays such a significant role in vascular endothelial
dysfunction, a number of pathologies are associated with insufficient NO bio-availability.
Oxidative stress, a causative agent of endothelial dysfunction, results from altered
intracellular signaling as a consequence of obesity, endothelial injury, or increased
circulating inflammatory signals (21). Hypertension, atherosclerosis, vascular
3

complications of diabetes, and stroke represent clinical presentations of long term
endothelial oxidative stress. Endothelial oxidative stress precipitates the onset endothelial
dysfunction by interfering with the catalysis of eNOS, or interacting with NO itself to
prevent its vasoactive characteristics (22). Oxidative stress is the result of increased ROS
including superoxide (O2.-), hydroxide ion (OH-), hydrogen peroxide (H2O2), and
peroxynitrite (ONOO-) (21). Increased intracellular ROS levels are generated by the
mitochondrial electron transport chain, isoforms of NADPH oxidase, xanthine oxidase,
cyclooxygenase, lipooxygenase, and uncoupled eNOS (23-25). The uncoupling of eNOS
is defined by the production of ROS or reactive nitrogen species (RNS) rather than NO
(26) due to insufficient arginine or reducing power from BH4 (reactions 2 -4) (17).
2 O2 + NADPH + H+  2 O2- + NADP+ + 2H+ (R2)
and/or
O2 + NADPH + H+  H2O2 + NADP+ (R3)
and/or
O2.- + NO  OONO- (R4)

There are multiple mechanisms that can lead to the uncoupling of eNOS in
endothelial cells, including increased oxidative stress that promotes S-glutathionylation,
increased asymmetric dimethylarginine (ADMA) production, oxidation of co-factors, or
low arginine levels (27-30). Oxidative stress often results in reduced NO availability
through the oxidation of the required co-factors (tetrahydrobiopterin (BH4), NADPH,
FMN, FAD) of eNOS leading to the generation of O2.- (27). S-glutathionylation is a posttranslational modification of proteins that serves as an adaptive response to high ROS
4

levels. eNOS S-glutathionylation can occur on cysteines 689 and 908 in response to
oxidative stress, which also results in the uncoupling eNOS (27). In addition, the
generation of ADMA, a competitive inhibitor of eNOS and biomarker for impaired
vascular health, occurs in response to oxidative stress through increased protein arginine
methyltransferase 1 (PRMT1) activity (31). ADMA concentration, and its inhibition of
eNOS, can be reduced by serving as substrate for dimethylarginine
dimethylaminohydrolase (DDAH) (32). An increase in PRMT1, a decrease in DDAH
activity, or altered balance between ADMA and arginine levels can consequently be
detrimental to endothelial function. As a result, maintaining available arginine
concentration for eNOS catalysis is critical in NO generation as well as preventing ROS
production. Therefore, the prevention of oxidative stress, adequate arginine/ADMA ratio,
and the maintenance of co-factors in their reduced form are important in supporting
endothelial function through the prevention of eNOS uncoupling.

eNOS regulation
As a consequence of the fact that uncontrolled eNOS activity can potentially be
damaging to the endothelium, eNOS is extensively regulated at the level of transcription,
through protein-protein interactions, as well as post translational modifications such as
phosphorylation, nitrosylation, and palmitoylation/ myristoylation, in order to modulate
eNOS activity as well as its subcellular targeting (33, 34). In addition, there are two
fundamental mechanisms of eNOS activiation, one is termed calcium-dependent, and the
other is calcium-independent (35, 36). During calcium-dependent activation, the
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stimulation of eNOS activity occurs through the direct interaction with activated
calmodulin (37). However, during calcium-independent activation, a series of
phosphorylation events occur that promote eNOS interaction with the activated
calmodulin that exists at basal calcium levels (38). Several phosphorylation sites of
eNOS have been identified, including S114, T495, S633, and S1177 (human sequence;
S116, T497, S635, and S1179 bovine sequence), with T495 and S1177 being the most
characterized (39). For bovine eNOS, the phosphorylation site T497 lies in the
calmodulin binding region and thus prevents calmodulin interaction and eNOS activity
when phosphorylated to reduce eNOS activity (40). Conversely, phosphorylation at
S1179 discourages phosphorylation at T497 and thus promotes calmodulin-binding and
increases eNOS activity. Thus, calcium-independent activation of eNOS occurs by
promoting dephosphorylation of T497 and phosphorylation of S1179, rendering the
enzyme more susceptible to basal levels of activated calmodulin (38).

Multiple protein-protein interactions also modulate eNOS regulation. Evidence
suggests that interaction with other proteins may play a role in eNOS targeting. For
example, Schilling et al (41) described two novel eNOS-interacting proteins named
NOSIP (for eNOS-interacting protein) and NOSTRIN (for eNOS-trafficking inducer),
both of which influence the subcellular localization of eNOS. For NOSIP, targeting of
eNOS to the cytoskeleton seems to be one of the protein’s major functions (42). On the
other hand, when NOSTRIN is overexpressed, this leads to the translocation of eNOS
from the plasma membrane to intracellular vesicular structures (43) possibly involving an
endocytic process (44)
6

In addition to phosphorylation or protein-protein interactions that regulate eNOS,
regulation of substrate availability is a critical aspect of eNOS regulation. The MichaelisMenten constant (Km) of eNOS is in the 3-5 µM range, however the total cellular arginine
concentration is in the 100-800 µM range, yet eNOS is rarely saturated with substrate, a
phenomenon termed the “arginine paradox” (45). An explanation for the arginine paradox
that is supported by findings in our laboratory and others is the existence of a subcellular
pool of arginine that is accessible by eNOS, while bulk cellular arginine is not accessible
(46-48). The maintenance of the arginine pool fated for eNOS catalysis is regulated by
the arginine recycling enzymes argininosuccinate synthase (AS) and argininosuccinate
lyase (AL) (49). AS, an ATP-dependent aspartate/citrulline ligase, catalyzes the rate
limiting step of eNOS derived citrulline to argininosuccinate in endothelial arginine
recycling (Reaction 5) (50, 51).
Aspartate + Citrulline + ATP + MgCl2  Argininosuccinate + AMP + PPi (R5)
2 Argininosuccinate  Fumarate + Arginine (R6)
AL converts argininosuccinate generated by AS to the arginine that is ultimately directed
to eNOS (Reaction 6) (51). The citrulline to arginine recycling by AS, AL, together with
NO production by eNOS is referred to as the citrulline-NO cycle (52, 53).

7

Arginine recycling and NO production*
AS expression is critical for the production of endothelial NO. The indication that
AS plays an essential role in supporting NO production developed from a series of
experiments using RNA interference to specifically silence AS expression in vascular
endothelial cells (54).Diminished levels of AS expression that resulted from siRNA
treatment were shown to correlate with impaired NO production in the presence and
absence of effectors (54). Unanticipated, however, was the significant loss of viable
endothelial cells observed after siRNA treatment. The fact that the loss of viability
followed reduced expression of Bcl-2, and an increase in caspase activity, strongly
suggested a relationship between impaired NO production and apoptosis. This
relationship was supported by the observation that exposure to a NO donor rescued cell
viability despite siRNA treatment (54). More importantly, these results demonstrated that
AS was required for the maintenance of basal production levels of NO in order to support
cell viability. In endothelial cells, AS and AL were shown to colocalize with eNOS and
specialized structures of the plasma membrane called caveolae (55, 56). Caveolar
domains assemble at the Golgi and traffic to the plasma membrane as stable transport
platforms (57).This may explain the subcellular association of eNOS with the Golgi and
perinuclear membrane (58-60).

AS regulation and NO production*
Although there has been much research conducted in the area of eNOS regulation,
AS regulation has not been fully explored. Early research from the 1970s revealed that
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hepatic AS is a critical component of the urea cycle (50). However, since the early
publications on AS, our understanding of the properties and biological role of this
enzyme has changed greatly. Initially, the non-hepatic role of this enzyme was assumed
to be minimal; and as such, the role and regulation of AS, outside of that needed for urea
production, developed slowly. However, interest in AS, and particularly its regulation,
has grown due in great part because of its involvement in NO production (52). In
humans, there are 15 copies of the AS gene, including 14 pseudogenes scattered across
the genome (61). The ASS1 gene, located on chromosome 9, appears to be the only
functional gene involved in AS expression. This is supported by the findings that
mutations in the chromosome 9 copy of ASS1 cause citrullinemia (62-64).

The AS promoter
About 800 bp of the promoter region for the human ASS1 gene have been
characterized (65) showing a TATA box, six potential Sp1 binding sites (GC boxes) and
one potential AP-2 site (65, 66). The three GC boxes in the immediate promoter were
shown to act synergistically and to be required in order to achieve full promoter
activation (66). Surprisingly, no CAAT sequence (C/EBP binding site), nor GRE
(glucocorticoid-responsive), or CRE (cAMP responsive-) elements were found in the
early characterization of the AS promoter. Recently, however, Guei et al (67), through
functional analysis of DNase I hypersensitive sites, located a cAMP response element for
the human ASS1 gene at ~10 kb upstream of the transcription start site. This discovery
helped reconcile earlier findings showing liver-specific enhancement of ASS1 gene
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expression by TSE1 (tissue-specific extinguisher locus 1) regulation (68, 69), and the fact
that transcription of the ASS1 gene in rat liver was stimulated by cAMP in nuclear run-on
assays (70). TSE1 encodes the regulatory subunit Rl alpha of protein kinase A (PKA)
(71). According to Tsai et al (72), the proximal region of the ASS1 promoter also contains
an E-box that is recognized by c-Myc and HIF-1alpha, as well as a GC-box that is
recognized by Sp4 in melanoma cells. Under non-induced conditions, the E-box element
bound HIF-1 alpha, and under induced conditions (arginine depletion) HIF- 1 alpha was
replaced by c-Myc, at least in two of the melanoma cell lines, but not in another (72). In
all cases, however, Sp4 was shown to constitutively bind the GC-box regardless of
arginine availability. Taken together, their results suggested that the transcriptional
induction of ASS1 expression, relative to arginine depletion, involved the interplay
between the positive transcriptional regulators c-Myc and Sp4, and the negative regulator
HIF-1alpha.

AS regulation by endothelial signaling
Since most all phenotypic properties of endothelial cells relate to nitric oxide
signaling, eNOS has been highly studied in response to physiological cues such as shear
stress and cytokines (73-76). On the other hand, relatively little is known about the
regulatory mechanisms that control AS expression in this context. Nevertheless, what has
been elucidated, thus far, has provided a picture that supports the central role of AS and
its coordinate regulation with eNOS in nitric oxide production. For example, Mun et al
(77) examined the differential expression of genes in human umbilical vein endothelial
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cells (HUVECs) under static and laminar shear stress conditions. Among the 20 genes
whose expression was increased by laminar shear stress conditions, and simultaneously
decreased by cellular senescence, was ASS1. Based on their findings, the authors
suggested that AS expression was critical both for basal and laminar shear stress-induced
nitric oxide production. This observation was consistent with Goodwin et al (54) who
demonstrated through siRNA knockdown studies, that AS expression was required to
support both basal and induced nitric oxide production in vascular endothelial cells.
Goodwin et al (78) also showed that both AS and eNOS expression were significantly
reduced by treatment with physiological levels of TNF-alpha in vascular endothlelial
cells. Not surprisingly, the loss AS and eNOS expression was accompanied by a dramatic
decrease in the capacity of the TNF-alpha-treated cells to produce nitric oxide. Moreover,
the down regulation of AS expression by TNF-alpha was shown to be mediated through a
similar transcriptional mechanism by which TNF-alpha down-regulates eNOS, involving
Sp1/Sp3 elements in the proximal promoter (73). Inhibitor studies suggested that
repression of AS expression by TNF-alpha was mediated, at least in part, via the NFkappaB signaling pathway (79). Critically, these results revealed the extent to which
TNF-alpha impairs vascular endothelial function via the coordinate down-regulation of
both eNOS and AS expression (78). On the other hand, the peroxisome proliferatoractivated receptor gamma (PPAR-gamma) agonist, troglitazone, was shown to support
nitric oxide production in vascular endothelial cells through the up-regulation of AS
expression (80). Because the induction of AS was inhibited by treatment with the
transcriptional inhibitor, 1-D-ribofuranosylbenzimidazole (DRB), this demonstrated that
troglitazone mediated its response essentially at the transcriptional level. In keeping with
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this finding, a distal PPAR-gamma response element (PPRE) at –2471 to –2458 was
identified that mediated the PPAR-gamma agonist response. These results extended the
repertoire of mechanisms by which PPAR-gamma agonists promote vascular health (81,
82). In the case of troglitazone, one of its vascular protective properties directly relates to
the maintenance of an adequate supply of arginine for nitric oxide production through the
up-regulation of AS (80). Less is known at a more global level involving co-regulators
and co-repressors that interact with specific transcription factors on the ASS1 gene
promoter to alter rate of expression. Thus, critical information related to the interplay of
promoter elements that allow tissue specific expression of AS is quite limited.

Regulation of AS localization
AS has been shown to associate with raft-like membrane microdomains, caveolae,
at the plasma membrane (55). The major constituent of caveolae is caveolin-1 (83),
which is expressed in many cell types, including endothelial and epithelial cells.
Importantly, a major phenotype of caveolin-1 knockout mice relates to nitric oxide
signaling. Nitric oxide release from caveolin-1-deficient cells is higher compared to
wild-type cells, and secondary effects of nitric oxide are increased, demonstrating
activation of eNOS through de-inhibition in the absence of caveolin-1 (84). Conversely,
direct binding of eNOS to the scaffolding domain (positions 82-101) of caveolin-1 has
been shown to decrease nitric oxide production in vitro and in cell culture (18, 56, 85).
However, little is known as to whether caveolin may play a similar role in affecting either
the activity or the subcellular localization of AS. Indeed, the only known factor shown to
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affect localization of AS is citrin, a mitochondrial aspartate/ glutamate carrier that
interacts with AS. Mutations in the SLC25A13 gene that encodes citrin were shown to
cause adult-onset type II citrullinemia (63). In this case, the mutated citrin does not allow
AS mitochondrial association. As a consequence, AS appears to be rapidly degraded
accounting for the low levels found in hepatocytes of affected individuals (63).

ARP regulation of AS
Open reading frames in the 5´-leaders of messenger RNAs are emerging as
important mediators of transcript-specific translational controls. In most instances,
upstream open-reading frames (uORFs) regulate the expression of a downstream ORF on
the same mRNA (cis-regulation). In this case, those mRNAs with uORFs are typically
expressed as the only species of that mRNA in a particular cell type (86). In contrast, the
transcription of AS mRNA, at least in vascular endothelial cells, is initiated from multiple
start sites, generating mRNAs with different lengths and overlapping 5´-untranslated
regions (UTRs) (87). In fact, nearly 10% of argininosuccinate transcripts are longer
variants that contain an out-of-frame, upstream open reading frame (uORF) encoding a
~2.2 kDa protein, referred to as AS Regulatory Protein (ARP). ARP downregulates AS
expression in trans at the translational level (88). Consistent with the rate-limiting role of
AS in the citrrulline/nitric oxide cycle, the increase in AS protein that resulted from the
knockdown of ARP was accompanied by an increase in nitric oxide production.
Likewise, when ARP was over-expressed in endothelial cells, AS expression was
suppressed, resulting in reduced nitric oxide production (88).

13

AS regulation by post-translational modification and protein-protein interaction
Since AS is responsible for maintaining the available arginine for varied
metabolic processes, it seems logical that acute or immediate changes in activity may also
be necessary to accommodate the multiple roles that the arginine product plays in cell
function. However, such immediate responses require regulation that goes beyond
changes in transcription. Nevertheless, there are very few documented reports that
discuss posttranslational events that may regulate the function of AS. In fact the bulk of
literature suggests that AS regulation occurs primarily at the transcriptional level (52).
There are, however, some recent findings that have changed this view. For example, it
has been reported that the NADPH sensor protein, HSCARG, interacts with AS to
downregulate its activity in epithelial cells (89). In fact, it has been suggested that the
protein-protein interaction of HSCARG with AS may provide a mechanism by which the
epithelial cell maintains an intracellular balance between its redox state and nitric oxide
levels. On the other hand, Hao et al (90) showed that human AS can be inactivated by
reversible nitrosylation at Cys-132 in response to lipopolysaccharide-treatment in both
cultured smooth muscle cells and in mice. Mutagenesis studies confirmed that the
nitrosylation of Cys-132 was both necessary and sufficient to inhibit AS. Based on their
results, the authors suggested that post-translational modification of AS by nitrosylation
might provide important feedback mechanism whereby nitric oxide can limit arginine
availability in nitric oxide producing cells (90). Possibly the first report demonstrating
that argininosuccinate was a phosphoprotein came in 2008 when Imani et al (91), using a
phospho-proteomic analysis, reported that AS in HeLa cells was a phosphoprotein.
However, their study did not consider the biological relevance of AS phosphorylation.
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Subsequently, Corbin et al (92) showed that AS was indeed phosphorylated in vascular
endothelial cells in response to VEGF treatment by protein kinase A (PKA).
Interestingly, PKA was already known to enhance nitric oxide production via
phosphorylation and activation of eNOS (59). Although reports on the post-translational
regulation of AS are presently meager in number, it is becoming clear that there exists an
assortment of new mechanisms that affect AS expression and activity. As such, AS offers
a distinctive paradigm for regulation that has expanded beyond transcriptional regulation
to now include localization, transcriptional, and post-translational controls. This array of
regulatory strategies which a cell uses to define and control arginine levels further
endorses the physiological significance of AS in mammalian endothelial homeostasis.

Specific Aims
Purpose
It has been demonstrated that eNOS requires arginine derived from arginine
recycling enzymes that is distinct from the bulk intracellular arginine pool, and without
AS expression, NO production does not occur and endothelial cells do not survive (54).
AS and eNOS have been isolated from caveolar fractions which suggests that arginine
recycling and eNOS catalysis of arginine must take place in proximity in order to
generate NO (55). eNOS associates with different compartments in the cell such as the
golgi apparatus, the plasma membrane, mitochondria, and the cytosol (93-95). Various
phosphorylation events as well as lipid modifications facilitate the translocation of eNOS
to its respective compartment where NO production is needed (96). It is known that AS
15

and eNOS are transcriptionally co-regulated in response to various physiological factors.
Importantly, Corbin et al have shown that AS exists as a phospho-protein in endothelial
cells, however the biological significance of this is not known (92). We have identified a
phosphorylation site at serine 328 (S328) of AS. The purpose of this research is to
identify the biological relevance of AS phosphorylation at S328 in order to further
characterize mechanisms by which AS contributes to NO production in endothelial cells.
The understanding of how eNOS is regulated through substrate availability in different
compartments of the cell will provide new insight for identifying novel therapeutic
targets in the treatment of cardiovascular disease and diabetes.

Central Hypothesis
Our central hypothesis is that AS is regulated by phosphorylation at S328 in
endothelial cells in order to mediate spatial and/or temporal regulation of the enzyme in
response to physiological cues that change the demand for NO (see working model,
Figure 1).

Specific Aim 1
Determine how physiological factors affect AS phosphorylation at S328 in
endothelial cells in relation to NO production. Endothelial nitric oxide synthase
(eNOS) is regulated post-translationally by phosphorylation in a spatial and temporal
manner to direct the amount and location of NO production in response to physiological
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factors (42). In addition to post-translational modification, eNOS is also regulated by
substrate availability (97). It is known that AS catalyzes the rate-limiting step in
citrulline-NO cycle (55, 98), however the post-translational regulation of AS relative to
physiological factors is largely unknown (92). We have previously identified serine 328
(S328) as a phosphorylation site of AS through mass spectrometry analysis, in silico
modeling, and subsequently developed a phospho-specific antibody against pS328. In this
specific aim, we investigated the conditions by which AS is phosphorylated at S328. Our
hypothesis for this aim was that AS is coordinately regulated with eNOS through
phosphorylation at S328 in order to efficiently and acutely respond to the cellular demand
for NO (described in Part I).

Specific Aim 2
Identify the relevant kinase(s) involved in phosphorylating AS at S328 in
endothelium in response to physiological factors. eNOS is regulated by
phosphorylation events prompted by physiological factors that signal to endothelial cells
to enhance or reduce NO production. Early evidence suggested that S328 was
coordinately regulated with the inactivating phosphorylation at threonine 497 (T497) of
eNOS. In this specific aim, we determined the kinase responsible for phosphorylating
S328. Our hypothesis was that kinases that target eNOS at T497 are responsible for
modifying S328 of AS (described in Part II).
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Specific Aim 3
Determine the effects of phosphorylation at S328 on AS activity and subcellular
localization. Some caveolin binding proteins, including eNOS, are known to associate
with lipid raft invaginations at the plasma membrane called caveolae (56) (99). Previous
data showed that AS interacts with caveolin under stimulatory conditions, and S328 of
AS resides 3 amino acids away from a putative caveolin binding motif. In this aim, we
investigated the effect of S328 phosphorylation on AS interaction with caveolin and AS
enzymatic activity. Our hypothesis was that AS phosphorylation at S328 will prevent
interaction with caveolin in order to regulate AS localization rather than enzymatic
activity (described in Part III).
* sections have been published in peer-reviewed journal; Haines, R. J., Pendleton, L. C.,
and Eichler, D. C. (2011) Argininosuccinate synthase: at the center of arginine
metabolism. Int J Biochem Mol Biol 2, 8-23
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Figure 1: Depiction of regulatory mechanisms proposed in specific aims. S328
phosphorylation modulates caveolin and/or membrane interaction under conditions that
affect NO production in endothelial cells.
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PART I: REGULATION OF ARGININOSUCCINATE SYNTHASE
PHOSPHORYLATION AT S328 RELATIVE TO ENDOTHELIAL TREATMENT
WITH PHYSIOLOGICAL FACTORS

Summary
Argininosuccinate synthase (AS) expression is critical for NO production in
endothelial cells. AS catalyzes the rate-limiting step in the arginine recycling required for
endothelial nitric oxide synthase (eNOS) substrate generation. Coordinate transcriptional
regulation of AS and eNOS occurs in response to a number of physiological factors,
however, little is known regarding post-translational regulation of AS. Here we identify a
novel phosphorylation site of AS at serine 328 (S328) that responds to several endothelial
stimuli in a coordinate fashion with eNOS S1179. Cultured bovine aortic endothelial cell
(BAEC) treatment with calcium-independent eNOS stimulation (insulin, VEGF, and
sodium vanadate) resulted in significant decrease in phosphorylation of AS at S328.
Conversely, BAEC treatment with calcium-dependent activation of eNOS resulted in
significant increase in phosphorylation of AS at S328. These results suggest that a
function of pS328 AS is to support NO production during calcium-dependent stimulation
of eNOS in endothelial cells.

Introduction
Argininosuccinate synthase (AS) is a critical enzyme involved in nitric oxide
(NO) production in the vascular endothelium (1). The expression of AS has been shown
to increase with eNOS expression in response to troglitazone (peroxisome proliferator
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activated receptor gamma (PPARγ) agonist) (2), insulin (3), and shear stress (4).
Likewise, the downregulation of both AS and eNOS has been demonstrated in response
to TNFα (5), and hypoxia (6). However, little is known relative to the regulation of AS
beyond the level of transcription.

Given the relationship with AS and NO production and the fact that NO cannot be
stored intracellularly, a logical supposition is that AS is acutely regulated (i.e. by posttranslational modification) in order to quickly respond to the cellular demands of NO.
Indeed, there are three known post-translational modifications: acetylation at lysine 165
(7), nitrosylated at cysteine 132 (8), and phosphorylated at serine 352 (human sequences)
(9), however the significance of the phosphorylation or acetylation is not known.
Consistent with the idea that AS post-translational modification has been suggested to
play a role in NO signaling, the S-nitrosylation of AS inhibits its activity when the
overproduction of NO occurs (10), potentially serving as a negative feedback loop for
NO production in endothelial cells. Furthermore, Corbin et al (11), through cultured
bovine aortic endothelial cell (BAEC) stimulation and phospho-protein enrichment
studies, demonstrated that phosphorylation of AS occurs in response to stimulation of NO
production with the physiological factor vascular endothelial growth factor (VEGF).
However, the location of the phosphorylation site was not determined at that time.

In order to identify potential sites for phosphorylation, mass spectrometry was
performed with AS purified from BAECs stimulated with factors including bradykinin
and okadaic acid (PP1/ PP2A phosphatase inhibitor), then subsequent in silico modeling
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studies were carried out (12) to determine relative kinase accessibility to the
serine/threonine sites identified by mass spectrometry. Two sites, serine 180 (S180) and
serine 189 (S189) were buried within the enzyme, and two sites threonine 131 (T131) and
serine 328 (S328) were on the exterior of the enzyme in an area considered readily
accessible for protein-protein interaction. Interestingly, S328 was proximal to a putative
caveolin binding motif (ɸXXXXɸXXɸ) where ɸ is any aromatic amino acid (tryptophan,
phenylalanine, or tyrosine) and X is any amino acid (13). Considering these data and
observations together, we invested in the production of a phospho-specific antibody
against phosphorylated S328 (pS328) (see experimental procedures).

To establish the potential involvement of pS328 AS in pathways relevant to
endothelial NO production, many treatments that are known to modulate NO generation
were utilized followed by western blotting to assess potential changes in phosphorylation.
Stimulators and inhibitors of endothelial NO production were used to treat BAECs in a
series of experiments. Stimulators of NO production used were: acetylcholine,
bradykinin, Nω-hydroxy-nor-arginine (Nor-NOHA, arginase inhibitor), estradiol, sodium
vanadate, insulin, VEGF, calcium ionophore, and lysophosphatidic acid (LPA). Inhibitors
of NO production used included free fatty acid (FFA), homocysteine (Hcy), TNFα, and
asymmetric dimethylarginine (ADMA) (see Table 1). Early experiments showed a
decrease in pS328 relative to the physiological stimulators of NO production, VEGF or
insulin. Therefore, the initial hypothesis of this study was that agents that stimulate NO
production lead to a decrease in pS328 of AS relative to non-treated cell lysates, and
inhibitors of NO production will lead to an increase pS328 of AS.
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Mechanisms that stimulate endothelial NO production
There are several signaling pathways for activation of eNOS in endothelial cells
including: calcium-dependent, calcium-independent (14), limiting substrate competition
(15), or activation of upstream kinases (16). In calcium-dependent stimulation of eNOS
(acetylcholine (17), bradykinin (17), estradiol (18), calcium ionophore), the activation of
eNOS requires the activation of calcium dependent calmodulin (CaM) (19). Therefore,
for calcium-dependent stimulation, an increase in the intracellular calcium concentration
either through calcium channels in the plasma membrane or from subcellular stores in the
endoplasmic reticulum (ER) is required. In calcium-independent stimulation of eNOS
(insulin (20), VEGF (21), LPA (22), sodium vanadate(23)), phosphorylation events
modulated by protein kinase B (or Akt) and phosphatases allow activated CaM present at
basal levels to interact with eNOS (16). The increased phosphorylation of eNOS at S1179
(via Akt activtation) and dephosphorylation at eNOS T497 (via protein phosphatase 1
(PP1) activity) poise eNOS to be more accessible to the activated CaM that is present at
basal levels. Therefore, the term “calcium-independent” is somewhat of a misnomer since
activated CaM is still required for eNOS activity; however the initial event in eNOS
activation during “calcium-independent” stimulation is not dependent on calcium.

In addition to calcium related signaling, limiting eNOS substrate competition also
stimulates NO production (24). Endothelial cells express both cytosolic arginase I and
mitochondrial arginase II for the catalysis of arginine to ornithine and urea (15). It has
been established that eNOS and arginase have access to sequestered pools of arginine not
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freely exchangeable with bulk intracellular arginine, and that inhibiting arginase with
Nor-NOHA stimulates eNOS activity (25). Competition between eNOS and arginase
exists because the arginase Km for arginine is in the 1-20 mM range, the eNOS Km is
much lower at 1-5 µM (26), yet the rate of catalysis (Vmax) for arginase is 1.4 mM ˖ min1

˖ mg-1, while the Vmax for eNOS is 900 µM ˖ min-1˖ mg-1(25). This indicates that arginase

catalyzes at a faster rate, but eNOS has a higher sensitivity for arginine (27).
Consequently, the endothelial expression of arginase I and II are considered an additional
point of regulation for eNOS. Additionally, a functional relationship between AS and
arginase exists in that hepatocyte AS catalyzes the rate-limiting step in urea synthesis
when the urea cycle is saturated with substrate (28). For these reasons, the arginase
inhibitor Nor-NOHA was used to determine whether phosphorylation at S328 of AS may
play a role in modulating NO production when eNOS has less competition for arginine.

Upstream signaling kinases affecting eNOS activation can also be modulated in
order to affect NO production. Sodium vanadate is a potent NO promoting agent in that it
is a tyrosine phosphatase inhibitor, as well as tyrosine kinase activator, that has been
shown to activate intrinsic tyrosine kinase activity of the insulin receptor (29) and
subsequent induction of the (PI3K/ Akt pathway) of eNOS activation. In addition,
experiments have indicated that vanadate stimulates the recruitment of HSP90, a
chaperone that stabilizes eNOS and promotes its activity (23). Unpublished data by
Corbin et al have demonstrated that HSP90 also associates with AS. Therefore, the
possibility of AS phosphorylation at S328 playing a role in sodium vanadate stimulation
of eNOS was assessed.
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Mechanisms that prevent endothelial NO production
A common co-morbidity with atherosclerosis is the existence of high levels (up to
800 µM (30)) of plasma free fatty acid (FFA). There are several ways that FFA
negatively effects vascular health, including induction of endothelial dysfunction.
Esenabhalu et al demonstrated that FFA impairs calcium signaling in endothelial cells
and negatively impacts NO production (31). Therefore, endothelial cell treatment with
FFA is a physiologically relevant means to determine whether S328 phosphorylation of
AS is affected by disruptions in calcium mediated signaling as it relates to NO
production.

Diabetes and metabolic syndrome are associated with elevated circulating
inflammatory cytokines, such as TNF α, relative to healthy individuals (32). Increased
TNF α leads to several clinical consequences associated with diabetes or metabolic
syndrome, including endothelial dysfunction. TNF α mediates its effects on NO
production largely by decreasing eNOS and AS expression (33), but also by decreasing
eNOS phosphorylation at S1179 (34, 35). In addition, TNF α signaling leads to NF-κB
activation in endothelial cells (36). NF-κB modulates transcription of genes associated
with endothelial inflammation, such as genes associated with adhesion molecule
expression, increasing macrophage infiltration of the vascular wall, and increased ROS
generation (37). Therefore, TNFα was used to treat cultured endothelial cells in order to
determine whether the phosphorylation of S328 may be involved in NF-κB signaling
pathway, or is possibly associated with the endothelial response to inflammation.
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Homocysteine (Hcy) is a metabolic intermediate generated by Sadenosylhomocysteine hydrolase in the methylation cycle. In the absence of critical cofactors (5-methyltetrahydrofolate, co-enzyme B12 and co-enzyme B6) required for the
conversion of Hcy to methionine, impaired Hcy renal clearance occurs and re-absorption
into the bloodstream contributes to hyperhomocysteinemia, a condition commonly due to
renal complications of diabetes (38). Hyperhomocysteinemia can impair endothelial
function by inhibiting DDAH (converts asymmetric dimethylarginine (ADMA), to
arginine, citrulline, and dimethylamine (39)) activity, thereby increasing ADMA
production. ADMA acts as a competitive inhibitor of eNOS and contributes to superoxide
generation by endothelial cells (40). In addition, Hcy was also shown to interfere with
eNOS activation by increasing eNOS phosphorylation at T497 (inhibits eNOS activity)
(41) or uncoupling eNOS (42). Therefore, endothelial treatment with Hcy or ADMA was
used to ascertain whether S328 phosphorylation of AS plays a role in regulating eNOS
substrate availability under mimicked conditions of hyperhomocysteinemia.

After multiple experiments with each treatment described, data were analyzed
and trends in phosphorylation were determined relative to the type of mechanism relating
to NO production in order to determine a potential pathway with pS328 AS involvement.
The results of these experiments showed that mechanisms involving the PI3K/Akt eNOS
activation pathway decreased phosphorylation of AS at S328, and mechanisms involving
eNOS activation via calcium-dependent stimulation increased phosphorylation of AS at
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S328. Altering arginase activity or competitive inhibition of eNOS did not significantly
affect AS phosphorylation at S328 under these conditions.

Experimental Procedures
Cell culture
Bovine aortic endothelial cells (BAECs) were isolated from whole bovine aorta as
described in (43) with modifications. Aortas were harvested, washed with PBS without
magnesium or calcium to remove blood, and lumenal surfaces were exposed by
longitudinal dissection followed by incubation with 0.1% collagenase for 10 minutes.
Endothelial cell isolation was achieved by rolling sterile swabs across surface, then
releasing cells by twirling swabs in 5 ml 1 g/L glucose, 10% FBS (HyClone) enriched
Dulbecco’s modified eagle medium (DMEM, Invitrogen) in 15 ml conical tubes. Tubes
were centrifuged 5 minutes at 1000 rpm at 4ºC then cells were resuspended in 6ml
DMEM + 10% FBS and plated in 25cm2 treated cell culture flasks. Authentication of
isolation of endothelial cells in culture was confirmed by flow cytometry. Cells were
passed after they reached confluence (approximately 6 days) into treated 6 well culture
plates. Sixteen hours before experiments, confluent cells were serum starved with
DMEM at 1g/L glucose supplemented with 0.1% BSA and 1mM glutamine without
phenol red. Treatments included incubation with acetylcholine (Sigma) at 50 µM, NorNOHA (EMD Chemicals) at 40 µM, sodium vanadate (Sigma) at 50 µM, estradiol at 100
nM, LPA (Enzo Biochem) at 10 µM, FFA (Sigma; linoleic acid and oleic acid, 2 mol/mol
albumin each) at 800 µM, TNFα (Sigma) at 10 ng/ml, ADMA (Sigma) at 100µM, insulin
(Sigma) at 100nM, VEGF (R & D Systems) at 100ng/mL, calcium ionophore A23187
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(Sigma) at 0.5 µM, bradykinin (Sigma) at 10 µM, incubation times are indicated in figure
legends. Control BAECs were treated with serum starve media only.

Western blot analysis
BAEC proteins were obtained by cell lysis in RIPA buffer supplemented with
protease and phosphatase inhibitors (Pierce) followed by scraping for collection. Crude
lysates were frozen at -20 ºC overnight, then vortexed at the maximum setting for
approximately 1 minute followed by centrifugation at 4ºC at 15,000 X g for 10 minutes to
pellet insoluble material. Protein concentration was determined with the BCA protein
assay (Pierce) and 20ug of each lysate, as well as a dual color stained protein marker
(Pierce) was loaded to 15 well 4-20% gradient polyacrylamide gels for SDS-PAGE (BioRad). Gels were run at 190 V for 50 minutes followed by PVDF transfer using the semidry method (Bio-Rad). Gels were placed on hydrated PVDF membranes sandwiched
between extra-thick filter pads saturated with transfer buffer. Sandwiches were placed in
a semi-dry transfer unit (Bio-Rad) and ran at 17V for 36 minutes. Blots were blocked for
1 hour followed by incubation with primary antibody (AS, eNOS, pS1179 eNOS, BD
Transduction Laboratories; pS328 developed by 21st Century Biochemicals). overnight at
4ºC followed by two 10 minute washes in TBST. Horseradish peroxidase (HRP)
conjugated secondary antibody was added at 1/50,000 and incubated for 1 hour. Blots
were washed again then incubated with enhanced chemiluminescent substrate (Pierce) for
5 minutes. Blots were exposed to autoradiograph film then developed in a Kodak film
processor. Developed films were further analyzed with a gel dock imager (Bio-rad) and
densitometry was calculated using the basic Quantity-One software package (Bio-Rad).
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Degree of phosphorylation was determined by dividing the densitometric value of the
phosphorylated moiety by densitometric value of the total protein moiety and expressed
as a percentage (i.e. (pS328 AS/ AS) *100) Change in phosphorylation relative to
treatment was assessed by subtracting the average treated degree of phosphorylation
determined by densitometry by average degree of phosphorylation measured in control
lysates. Statistical comparison was performed between degree in phosphorylation of
treated vs. non-treated for each site with the students t-test.

Argininosuccinate Synthase Phosphoserine-S328 Specific antibody
A phospho-specific antibody against pS328 AS was developed to use for
phospho-AS detection in western blot analysis, immunoprecipitation, and confocal
microscopy. The following procedure was carried out by 21st Century Biochemicals.
The phospho-peptide corresponding the AS sequence 322-335: RR-AhxYGFWH[pS]PECEFVR-amide was synthesized then purified via high performance
liquid chromatography followed by sequence confirmation using combined CID MS and
QSTAR XL Pro. The phospho-peptide was then used to immunize 2 rabbits with 4
booster immunizations each.

Three test bleeds from each animal were sent to our laboratory to ensure antigen
specificity prior to animal sacrifice. Specificity to the phospho-peptide sequence
(corresponding the AS sequence 322-335: RR-Ahx-YGFWH[pS]PECEFVR-amide) was
determined by phospho-peptide competition compared to nonphospho-peptide
competition (corresponding the AS sequence 322-335: RR-Ahx-YGFWHSPECEFVR-
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amide). Test bleed sera containing phospho-specific antibody was blocked with
phospho-peptide then used to probe for phospho-AS via western blotting. Per the
antibody and peptide manufacturing facility, a 200-fold molar excess of the peptide is
required to effectively block antibodies for an immunoassay procedure. Therefore, either
phospho-specific peptide or nonphospho-specific peptide was diluted to 1.334 M, and
pS328 AS antibody was diluted to 0.0033 M with 5 ml blocking buffer (StartingBlock
(PBS) blocking buffer, Thermo Scientific) and allowed to pre-incubate for 30 minutes.
Blocked antibodies were then used to probe PVDF membranes with 20 µg of non-treated
BAEC lysates in each lane (see western blotting procedure above), followed by
secondary detection with anti-rabbit HRP and banding patterns of each lane were
compared. Following the assessment of antigen specificity of test sera, animals were
sacrificed and sera were affinity purified individually (i.e. not pooled) by 21st Century
Biochemicals, Inc. The antibody was supplemented with 30% glycerol, aliquotted and
stored at -80ºC for future use.

Upon receipt of affinity purified antibody, peptide-competition experiments were
repeated to ensure integrity and specificity of the antibody post purification. Additionally,
BAEC lysates were immunoprecipitated and subjected to western blotting in order to
ensure the antibody detects AS protein. Immunoprecipitation experiments were
conducted using the Dynabeads Immunoprecipitation kit (Invitrogen) per the
manufacturer’s instructions. The kit functions by coupling antibody via M-270 Epoxy to
magnetic beads followed by a series of washes to remove non-specifically bound
antibody. The advantage of coupling the antibody to the beads is that the heavy chain and
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light chain of the antibody used to immunoprecipitate does not elute with proteins of
interest. Non-treated BAECs were lysed with low detergent RIPA buffer (150mM NaCl,
50mM Tris/HCl pH 7.4, 1% NP-40, 0.25% Sodium deoxycholate, 1mM EGTA, 0.1%
Brij 35), protease and phosphatase inhibitor cocktail at 1/100 (Pierce)) and centrifuged at
4ºC , 15, 000 rpm for 10 minutes to remove unsoluble cellular components. Six
micrograms of each antibody (AS antibody, BD Transduction Laboratories; pS328
developed by 21st Century Biochemicals, Inc) was used to couple to beads followed by
overnight incubation with 2 mg of BAEC lysate protein. Beads were washed 4 times with
RIPA buffer, then proteins were eluted with elution buffer. Thirty microliters of each
eluate was subjected to SDS-PAGE and subsequent western blotting.

Nitric oxide determinations
Nitrite measurements were assayed using the fluorescent probe 2,3diaminonaphthalene (DAN) (Sigma) assay as described by (44) with modifications.
Briefly, during BAEC treatments extracellular media was collected after 15 minute
incubation with cells at 37ºC and 5% CO2 and immediately stored at -20ºC overnight in
tubes with limited head space. Ten milliliters of non-treated media was stored in -20ºC
overnight to use for standard curve generation in DAN assay. A standard curve was
generated by serially diluting 3µM sodium nitrite in media 4 times to yield concentrations
of 2µM, 1µM, 0.5µM, and 0.25µM. Sample aliquots were thawed at room temperature
and 100µl of each sample were added in triplicate to a 96 well plate. DAN reagent
(33µg/ml) was prepared in 0.62 M HCl and 15µl was added to each sample and standard
then allowed to incubate at room temperature for 15 minutes. The reaction was stopped
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with the addition of 30µl 2.8 M NaOH and plates were read on a BMG Fluostar Galaxy
Spectrofluorometer with 360 nm excitation and 405 nm emission. Data are described as
pmol nitrite per microgram protein.

Results
Anti-pS328 AS antibody is specific to target
A phospho-specific antibody against pS328 AS was developed to use for western
blot analysis of treated BAEC lysates. In order to ensure antibody specificity, peptide
competition and immunoprecipitations were carried out. Since the antibody of interest
binds to the phospho-peptide used to immunize rabbits for antibody production,
incubating the phospho-peptide with the antibody was expected to prevent the ability of
the antibody to detect the protein of interest in a western blot of BAEC lysates.
Therefore, phospho-peptide (AS sequence: 322-335: RR-Ahx-YGFWH[pS]PECEFVRamide) block versus nonphospho-peptide (AS sequence: 322-335: RR-AhxYGFWH[S]PECEFVR-amide) block of purified pS328 AS antibody was used to
determine specificity as well as approximate molecular weight of the pS328 moiety of
AS. Western blot analysis with the same BAEC lysates demonstrated that the antibody
blocked by phospho-peptide showed the absence of a ~51 kDa band that was present in
the nonphosphorylated-peptide block of the antibody (Figure 2A). In order to ensure that
the antibody was detecting AS protein, immunoprecipitation of non-treated BAEC lysates
using the pS328 AS antibody or commercially available monoclonal AS antibody was
performed. Upon western blot of immunoprecipitated proteins, the monoclonal AS
antibody detected the 48 kDa band known to be AS in lanes where total AS was
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immunoprecipitated, and additionally detected the ~51 kDa band identified by peptidecompetition (Figure 2B). Importantly, the monoclonal antibody against AS did not detect
a 48 kDa band in lanes where pS328 was immunoprecipitated. These data suggest that
the antibody is specific for pS328 AS protein at the AS sequence: 322YGFWH[pS]PECEFVR -335.

Calcium-independent eNOS stimulation decreased AS S328 phosphorylation
Calcium-independent induction of eNOS activity was performed with BAECs
treated with insulin, VEGF, LPA. or sodium vanadate. Lysates were assayed for
phosphorylation at pS1179 of eNOS as evidence of eNOS activation. Similar to previous
reports, insulin (20) (Figure 14A) , VEGF (45) (Figure 14C), and vanadate (23) (Figure
3A, densitometry 3B) increased phosphorylation at S1179 of eNOS. Importantly, AS
S328 phosphorylation significantly decreased in response to treatment with insulin,
VEGF (Figure 14), and sodium vanadate. Unexpectedly, LPA showed a decrease in
phosphorylation at eNOS S1179 and at AS S328 (Figure 4A, densitometry 4B). To
establish physiological relevance, culture media of treated cells was assayed for NO
production. Consistent with reported values, NO production increased relative to insulin
(46), VEGF (47), and sodium vanadate (23), however LPA treatment did not lead to an
increase in NO production as previously reported (20). Collectively, these results
suggested that phosphorylation of AS at S328 does not play a role in the endothelial
stimulation associated with insulin, VEGF, LPA, or sodium vanadate treatment. In
addition, these results support the idea that endothelial stimulation leads to decreased AS
phosphorylation at S328.
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Calcium-dependent eNOS stimulation increased AS S328 phosphorylation
To induce calcium-dependent eNOS stimulation, acetylcholine, estradiol, calcium
ionophore, or bradykinin were used to treat cultured BAECs. Following treatment, cells
were lysed and assayed for relative changes in phosphorylation of eNOS pS1179 and AS
pS328. Since the response of eNOS phosphorylation at S1179 is known to increase
relative to these treatments, increased phosphorylation at S1179 of eNOS served as a
positive control. As expected, when lysates were assayed for phosphorylation at S1179 of
eNOS, increased phosphorylation occurred in response to calcium ionophore (Figure 16),
bradykinin (Figure 5A, densitometry 5B), and acetylcholine (Figure 6A, densitometry
6B). However, increase in phosphorylation of eNOS at S1179 was not observed in
response to estradiol as described (18) (Figure 7A, densitometry 7B). Contrary to the idea
that stimulation of NO production may lead to a decrease in AS pS328, calciumdependent stimulation with bradykinin (Figure 5A, densitometry 5B), calcium ionophore
(Figure 16), and acetylcholine (Figure 6A, densitometry 6B) significantly increased
phosphorylation at S328 of AS relative to non-treated cells. In order to establish
physiological relevance, NO measurements were taken from culture media of treated
cells. As indicated in Figures 5C, 6C, and X, augmented NO production relative to nontreated cells was observed for bradykinin, acetylcholine, and calcium ionophore, however
estradiol failed to increase NO as previously reported (18) (Figure 7C).These results
suggested that phosphorylation of AS S328 and eNOS pS1179 may be co-regulated in
response to bradykinin, calcium ionophore, and acetylcholine.
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Suppressed arginase activity does not affect AS S328 phosphorylation
Since arginase is known to play a significant role in the regulation of NO
production by competing with eNOS for substrate (15), and AS has a functional
relationship with arginase in the liver (1), the possibility of phosphorylation of AS at
S328 being affected by changes in arginase activity was assessed. Experiments were
performed to determine whether changes in phosphorylation of AS at S328 occurred in
response to inhibited arginase activity by endothelial treatment with the synthetic
arginine anolog Nor-NOHA. The phosphorylation state of eNOS relative to Nor-NOHA
is not currently described, however, the degree of eNOS S1179 phosphorylation was
determined in these experiments for consistency. As shown in Figure 8C, robust
stimulation in NO production was observed in response to arginase inhibition with NorNOHA, indicating stimulation of NO production, however change in phosphorylation of
eNOS at S1179 relative to non-treated cells was not observed as shown in Figure 8A
(densitometry 8B). Similarly, AS pS328 did not change in response to endothelial
arginase inhibition (Figure 8A, densitometry 8B). These results indicate that arginase
inhibition does not lead to regulation of eNOS at S1179 nor AS at S328.

Competitive inhibition of eNOS activity does not affect AS S328 phosphoryaltion
Hcy acts to downregulate NO production by promoting ADMA elevation and
eNOS uncoupling and superoxide generation in endothelial cells (42, 48). ADMA is a
competitive inhibitor of eNOS and stimulates NADPH oxidase activity thereby serving as
a source for superoxide generation as well. (40). Either Hcy or ADMA were used to treat
endothelial cells in order to determine whether a relationship exists between
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phosphorylation of AS at S328 and oxidative stress or competitive inhibition of eNOS.
As shown in Figure 9A (densitometry 9B), phosphorylation at S1179 diminished in
response to Hcy as described by other reports (49). Also consistent with previous studies
(50), NO production was strongly inhibited in response to Hcy (Figure 9C). However, AS
S328 phosphorylation did not decrease to the degree of eNOS pS1179 (Figure 9A,
densitometry 9B). Similarly, ADMA treatment led to decreased phosphorylation at S1179
of eNOS (Figure 10A, densitometry 10B), however decrease in S328 phosphorylation
nearly reached significance (p<0.06, Figure 10A, densitometry 10B). BAECs responded
physiologically to ADMA as shown by significantly reduced NO production (Figure
10C) as previously reported. Taken together, these nearly significant changes in pS328
shown here indicate that ADMA or Hcy treatment leading to eNOS uncoupling and/or
increased oxidation may impact AS pS328 regulation. To resolve the precise changes in
phosphorylation at S328 relative to superoxide generation, experiments associated with
superoxide generation by eNOS or NADPH oxidase individually may give more insight.

Calcium signaling interference via FFA decreased AS S328 phosphorylation
A primary mechanism involved in the FFA mediated inhibition of NO production
involves the depletion of intra-endothelial calcium and subsequent dephosphorylation of
eNOS (31, 51, 52). Therefore, BAECs were treated with FFA (linoleic and oleic free fatty
acids) to ascertain the effects of altered calcium signaling on AS pS328. As shown in
Figure 11A (densitometry 11B), significant reduction in phosphorylation of AS at S328
and S1179 of eNOS was observed in FFA treated cells. In addition, FFA reduced NO
production, however results were highly variable and therefore not significantly different
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from non-treated cells (Figure 11C). These results suggest that dephosphorylation of AS
at S328 is co-regulated with dephosphorylation of eNOS S1179 in response to FFA
mediated signaling in endothelial cells.

TNFα decreased AS S328 phosphorylation
Since endothelial exposure to TNFα elicits endothelial dysfunction by impairing
eNOS phosphorylation at S1779 (34, 35),as well as increasing NF-κB activity (36), TNFα
was used to treat BAECs to determine potential effects on AS pS328. As shown in Figure
12A (densitometry 12B), phosphorylation of eNOS at S1179 was significantly reduced
and NO production was inhibited (Figure 12C) as shown previously (35). In addition, AS
S328 phosphorylation was significantly reduced in response to TNFα treatment. This
suggests that phosphorylation at S328 is not involved in endothelial response to TNFα,
and supports the idea that a co-regulatory relationship exists between AS pS328 and
eNOS pS1179 under these conditions.

Discussion
In this series of experiments, we showed that AS is regulated by phosphorylation
at S328 as the result of physiological treatment of endothelial cells with the use of a
custom antibody directed against pS328 AS. We showed that the antibody is specific for
the phosphorylated peptide composed of the AS sequence 322-[pS328]-335. Antibody
specificity was determined by peptide competition with either phosphorylated [pS328]
peptide or non-phosphorylated peptide, both peptides correlating to the AS sequence 322335. The competition showed that a ~51kDa band present in westerns performed with
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non-phosphorylated 322-335 peptide blocked antibody was absent in westerns blocked
with phosphorylated peptide 322-335. These results indicate that the detection of the
51kDa band was inhibited when blocked with phospho-peptide, and the antibody is
specific to pS328 because phospho-null-peptide did not effectively block detection.
Furthermore, this 51kDa band was the only band that was blocked by pS328 peptide from
test-bleed sera or purified antibody. Thus, the pS328 moiety of AS detected with this
antibody runs at a molecular weight of ~51kDa. The molecular weight of AS is
established to be ~48 kDa, approximately 3kDa smaller than the molecular weight
observed for pS328 AS. This perceived shift in molecular weight in SDS-PAGE analysis
often occurs due to the added phosphate group (53). In addition to peptide competition,
we performed immunoprecipitated enrichment of pS328 AS and observed detection of a
~51kDa band in IP eluates with commercially available monoclonal AS antibody,
indicating that the custom antibody does indeed detect the AS protein.

With an antibody that reliably detects pS328 AS, we were able to further
characterize S328 relative to stimulation of endothelial NO production. Since our
laboratory has shown changes in AS regulation with respect to insulin and VEGF, we
chose these factors to observe a potential regulatory role of S328 in these pathways. The
pathways of insulin (20), VEGF (45), and reportedly LPA (22), stimulate NO production
in a calcium-independent manner by way of phosphoinositol three kinase (PI3K)
activation leading to stimulation of Akt and subsequent increase in eNOS activity.
Although LPA has been reported to function by stimulating eNOS in a calciumindependent manner, this was not shown in these experiments. Nevertheless, the LPA

51

mechanism that impacts endothelial cells does so in a manner that decreased
phosphorylation at eNOS at S1179 and at AS S328. Regardless of the mechanism, these
data suggested that AS S328 and eNOS S1179 may be co-regulated under these
conditions.

With the use of established Akt dependent stimulators of eNOS, insulin and
VEGF, we did achieve activation of eNOS evident by increased phosphorylation at
S1179. Although we have previously reported that VEGF increased phosphorylation of
AS (11), the phosphorylation site was not identified, therefore it is likely that AS has an
additional phosphorylation site that responds differently to VEGF than pS328 (discussed
in greater detail in Part II). The observation that pS328 AS decreased upon calciumindependent activation of eNOS suggested that the kinase responsible for
phosphorylating S328 may be inhibited under this signaling cascade. It also suggested
that the phosphatase associated with pS328 may be up-regulated in response to insulin or
VEGF. Since phosphatases are much fewer in number and therefore very promiscuous,
identifying the kinase involved with S328 phosphorylation may provide more insight
relating to the mechanism this regulatory element may be associated. Therefore, possible
endothelial kinases that are inhibited by insulin or VEGF signaling may be responsible
for phosphorylating AS at S328, and are worth further investigation to determine the
function of pS328. The details of this investigation will be discussed in Part II.

Relative to calcium-dependent stimulation of eNOS, we showed that the AS S328
is regulated in a coordinate fashion with eNOS S1179 (promotes eNOS activity) in
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response stimulation with bradykinin, acetylcholine, and calcium ionophore. Although
these findings showed that the increase in bradykinin stimulated S1179 phosphorylation
was not significant, there is a strong literature base that has established that bradykinin
promotes eNOS phosphorylation at S1179 (54, 55). With an increased sample size, it
likely would have been shown here as well. Nevertheless, the demonstrated consistency
by which eNOS S1179 and AS S328 phosphorylation occurs in response to acetylcholine
and calcium ionophore coupled with the consistent decrease of only AS S328
phosphorylation in response to insulin or VEGF suggest that a function of pS328 AS may
be to support NO production during calcium-dependent stimulation of eNOS.

In terms of eNOS regulation, increased intracellular calcium regulates its
dissociation with the plasma membrane caveolin, a required event in eNOS activation
(56). Interestingly, AS has a putative caveolin binding motif (ϕXXXϕXXϕ , where ϕ
represents an aromatic amino acid: tryptophan, phenylalanine, or tyrosine and X any
amino acid (13)) corresponding to the AS sequence 317-FAELVYTGF-325 (Corbin et al,
unpublished) that is proximal to S328. Therefore, phosphorylation at S328 may regulate
interaction with caveolin. While eNOS does not have a phosphorylation site near its
caveolin binding motif, it does have a phosphorylation site, T497, that prevents its
association with calcium activated calmodulin, a protein-protein interaction required for
eNOS activation (57). The regulatory role of T497 that precludes the protein: protein
interaction with calmodulin serves as functional example for the idea that the
phosphorylation at or near a protein interaction site may hinder interaction with its
cognate protein. Therefore, a potential function of phosphorylation at S328 may be to
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hinder AS association with caveolin under calcium stimulated conditions. This
hypothesis was tested and will be described in Part III.

In agreement with the observation that calcium-dependent activation of eNOS
was associated with increased AS phosphorylation at S328, FFA, a physiological factor
reported to diminish intracellular calcium in endothelial cells (31), showed a significant
reduction in phosphorylation at AS S328 and eNOS 1179. In addition, endothelial
exposure to high concentrations of FFA is associated with NF-κB activation and therefore
up-regulates the expression of multiple genes associated with inflammation and ROS
production, a pathway that has been identified to decrease phosphorylation of eNOS at
S1179 (58). Therefore, the observed decrease in phosphorylation of AS at S328 and
eNOS at S1179 may be a result of NF-κB activation as well. Further evidence for this
conclusion was shown in this report with TNFα treatment, another factor that activates
NFκB (35), which showed a decrease in pS328 AS and pS1179 eNOS. Therefore, the
coordinate dephosphorylation of AS S328 and eNOS S1179 may also be associated with
pathways leading to NFκB activation, or an effect of increased ROS generation.

ROS generation also occurs by way of ADMA or Hcy treatment of endothelial
cells (48). Multiple mechanisms exist for Hcy mediated ROS generation and eNOS
inhibition, including increased oxidant stress, eNOS uncoupling (42), ADMA generation
(48), inhibition of S1179 phosphorylation (49), reducing BH4 levels (50), and NF-κB
activation (59). That being the case, it is clear how the consequences of Hcy treatment
would decrease S1179 phosphorylation. However, the interplay between these
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mechanisms leading to little observed change in AS S328 phosphorylation relative to Hcy
or ADMA treatment is less clear. Although,it may also be possible that the discordant
regulation of AS S328 and eNOS S1179 is a mechanism by which Hcy or ADMA induce
endothelial dysfunction.

Consistent with the idea that pS328 AS and pS1179 are coordinately regulated, no
change in phosphorylation at eNOS S1179 nor AS S328 occurred in response to
treatment with Nor-NOHA, or estradiol (results summarized in Table 2). In the case with
Nor-NOHA treatment, limiting substrate competition for eNOS likely does not require
additional regulation at S1179 for increased NO production. Since a basal level of
activated eNOS occurs under non-stimulated conditions, increasing available substrate
would result in increased NO production. The observation that regulation of AS at S328
is also not apparent relative to Nor-NOHA treatment serves as further evidence that S328
and S1179 are regulated in a coordinate fashion. Consistent with this reasoning, estradiol
treatment showed no change in NO production nor phosphorylation at S1179, indicating
that intracellular calcium was not increased by estradiol under these conditions.
Therefore, cells were not responding to estradiol in a manner that is relevant to NO
production. The observation that S328 phosphorylation was also not responsive to
estradiol suggested that the pathways governing regulation at AS S328 and eNOS S1179
were not elicited by estradiol, further supporting the idea that these sites are co-regulated.

Collectively, these results suggest that pathways associated with calcium
mediated phosphorylation of eNOS at S1179, but not calcium-independent
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phosphorylation of eNOS, are coordinately regulated with AS S328 phosphorylation.
Furthermore, inhibition of NO production with FFA or TNFα decreased phosphorylation
at AS S328 and eNOS S1179, again supporting the idea that these sites are co-regulated
under these conditions. The hypothesis that S328 phosphorylation is calcium-dependent
will be assessed in the next section.
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Table 1. Effect of physiological factors on eNOS activity. Agents used to establish the
role phosphorylation of AS at S328 has in the production of NO.

Acetylcholine
(Ach)
Bradykinin
(BK)
Estradiol

Stimulate

Agent
Endogenously
Produced
Yes

Stimulate

Yes

Stimulate

Yes

LPA

Stimulate

Yes

Insulin

Stimulate

Yes

VEGF

Stimulate

Yes

Nor-NOHA

Stimulate

No

Na Vanadate

Stimulate

Trace levels

Free Fatty
Acid (FFA)
TNFα

Inhibit

Yes

Inhibit

Yes

ADMA

Inhibit

Yes

Homocysteine
(Hcy)

Inhibit

Yes

Agent

Effect on NO
Production

Mechanism of
eNOS
Regulation
Calciumdependent
Calciumdependent
Calcium
dependent
Calciumindependent
Calciumindependent
Calciumindependent
Inhibits
arginase
Calciumindependent
Alters calcium
Downregulates
eNOS
expression
eNOS
competitive
inhibitor
Uncouples
eNOS,
ADMA

Reference
(16)
(16)
(17)
(21)
(19)
(20)
(24)
(22)
(30)
(33, 34)

(39)

(38,41)
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Table 2. Summary of Changes in eNOS and AS Phosphorylation Relative to Treatment.
The observed effects on eNOS phosphorylation at S1179 and AS phosphorylation at
S328 relative to different mechanisms of NO stimulation. Bolded items represent a
common change in phosphorylation between eNOS S1179 and AS S328.

Treatment

Known
effect on
NO
production

Acetylcholine
(Ach)
Bradykinin
(BK)
Estradiol

Stimulate

LPA

Stimulate

Insulin

Stimulate

VEGF

Stimulate

Nor-NOHA

Stimulate

Na Vanadate

Stimulate

Free Fatty
Acid (FFA)
TNFα

Inhibit

ADMA

Inhibit

Stimulate
Stimulate

Inhibit

Homocysteine Inhibit
(Hcy)

Observed effect
on pS1179
eNOS

Observed effect
on pS328 AS

Calciumdependent
Calciumdependent
Calcium
dependent
Calciumindependent
Calciumindependent
Calciumindependent
Inhibits
arginase
Calciumindependent
Alters calcium

Increase

Increase

Increase

Increase

No change

No change

Decrease

Decrease

Increase

Decrease

Increase

Decrease

No change

No change

Slight
increase
Decrease

Decrease

Downregulates
eNOS
expression
eNOS
competitive
inhibitor
Uncouples
eNOS,
ADMA

Decrease

Decrease

Decrease
(slight)

Decrease
(slight)

Decrease

No change

Mechanism of
eNOS regulation

Decrease
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Figure 2: Custom antibody is specific to pS328 AS. Rabbits were immunized with AS
sequence 322-335: RR-Ahx-YGFWH[pS]PECEFVR-amide then sacrificed. Antibody
was purified by affinity chromatography then analyzed for specificity. (A) BAEC lysates
were subjected to SDS-PAGE then transferred to PVDF. Lanes were cut into strips then
incubated with antibody without peptide (left lane),with non-phosphorylated peptide
(middle lane), or with phospho-peptide (right lane). Blots are representative of 4
experiments. (B) Non-treated BAEC lysates were immunoprecipated (IP) with either
anti-V5 tag (Lane 1; negative control), commercially available AS antibody (Lanes 2 and
3), or custom anti-pS328 antibody (Lanes 4 and 5) then IP eluates were analyzed by
western blot with monoclonal anti-AS immunodetection. Bottom blot represents lighter
exposure of the upper blot. Blot is representative of 5 experiments.
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Figure 3. Sodium vanadate treatment of BAECs showed decreased phosphorylation of
AS at S328 and increased phosphorylation of eNOS at S1179. BAECs were serum
starved 16 hours then treated with sodium vanadate or serum starve media alone for 1
hour. (A) Western showing relative change in phosphorylation of AS at S328 and eNOS
at S1179. (B) Quantitation of densitometry represents the change in AS S328 and eNOS
S1179 phosphorylation of treated lysates relative phosphorylation present in non-treated
lysates. GAPDH expression was used as loading control. Changes in phosphorylation are
statistically significant (n=4, *p<0.05). (C) DAN assay for NO production in extracellular
culture media of vanadate stimulated cells showed a statistically significant increase in
NO production relative to non-treated cells.
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Figure 4. LPA treatment of BAECs showed decreased phosphorylation of AS at S328 and
eNOS at S1179. BAECs were serum starved 16 hours then treated with LPA or serum
starve media alone for 1 hour. (A) Western showing relative change in phosphorylation
of AS at S328 and eNOS at S1179. (B) Quantitation of densitometry represents the
change in AS S328 and eNOS S1179 phosphorylation of treated lysates relative
phosphorylation present in non-treated lysates, n=2. GAPDH expression was used as
loading control (not shown). Changes are not considered statistically significant because
of the small sample size. (C) DAN assay for NO production in extracellular culture media
of treated and non-treated cells showed that there is not a significant difference in NO
production between treated and non-treated cells.
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Figure 5. Bradykinin (BK) treatment of BAECs showed increased phosphorylation of AS
at S328 and eNOS at S1179. BAECs were serum starved 16 hours then treated with BK
or serum starve media alone for 30 minutes. (A) Western showing relative change in
phosphorylation of AS at S328 and eNOS at S1179. (B) Quantitation of densitometry
represents the change in AS S328 and eNOS S1179 phosphorylation of treated lysates
relative phosphorylation present in non-treated lysates, n=4. GAPDH expression was
used as loading control (not shown). Change in phosphorylation of pS328 was significant
(* p<0.05). Change in S1179 phosphorylation did not reach significance (p<0.07) (C)
DAN assay for NO production in extracellular culture media of treated and non-treated
cells showed significant (n=4, *p<0.05) increase in NO production as the result of BK
treatment.
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Figure 6. Acetylcholine (Ach) treatment of BAECs showed increased phosphorylation of
AS at S328 and eNOS at S1179. BAECs were serum starved 16 hours then treated with
Ach or serum starve media alone for 1 hour. (A) Western showing relative change in
phosphorylation of AS at S328 and eNOS at S1179. (B) Quantitation of densitometry
represents the change in AS S328 and eNOS S1179 phosphorylation of treated lysates
relative phosphorylation present in non-treated lysates, n=4. GAPDH expression was
used as loading control (not shown). Changes are not considered statistically significant
because of high variability. (C) DAN assay for NO production in extracellular culture
media showed statistically significant (n=4, * p<0.05) increase in NO production by
treated cells relative to non-treated.
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Figure 7. Estradiol treatment of BAECs showed no change in phosphorylation of AS at
S328 or eNOS at S1179. BAECs were serum starved 16 hours then treated with estradiol
or serum starve media alone for 1 hour. (A) Western showing relative change in
phosphorylation of AS at S328 and eNOS at S1179. (B) Quantitation of densitometry
represents the change in AS S328 and eNOS S1179 phosphorylation of treated lysates
relative phosphorylation present in non-treated lysates, n=2. GAPDH expression was
used as loading control (not shown). Changes are not statistically significant. (C) DAN
assay for NO production in extracellular culture media of treated and non-treated cells
showed no change between the two groups.
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Figure 8. Arginase inhibition with Nor-NOHA treatment of BAECs showed no change in
phosphorylation of AS at S328 or eNOS at S1179. BAECs were serum starved 16 hours
then treated with Nor-NOHA or serum starve media alone for 1 hour. (A) Western
showing relative change in phosphorylation of AS at S328 and eNOS at S1179. (B)
Quantitation of densitometry represents the change in AS S328 and eNOS S1179
phosphorylation of treated lysates relative phosphorylation present in non-treated lysates,
n=2. GAPDH expression was used as loading control (not shown). Changes are not
considered statistically significant because of the small sample size. (C) DAN assay for
NO production in extracellular culture media showed increased NO production in treated
cells relative to non-treated cells.
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Figure 9. Homocysteine (Hcy) treatment of BAECs showed a slight decrease in
phosphorylation of AS at S328 and stronger decrease in phosphorylation of eNOS at
S1179. BAECs were serum starved 16 hours then treated with Hcy or serum starve
media alone for 1 hour. (A) Western showing relative change in phosphorylation of AS at
S328 and eNOS at S1179. (B) Quantitation of densitometry represents the change in AS
S328 and eNOS S1179 phosphorylation of treated lysates relative phosphorylation
present in non-treated lysates, n=2. GAPDH expression was used as loading control (not
shown). Changes are not considered statistically significant because of the small sample
size. (C) DAN assay for NO production in extracellular culture media showed decreased
NO production by Hcy treated cells relative to non-treated.
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Figure 10. Asymmetric dimethylarginine (ADMA) treatment of BAECs showed
decreased phosphorylation of AS at S328 and eNOS at S1179. BAECs were serum
starved 16 hours then treated with ADMA or serum starve media alone for 1 hour. (A)
Western showing relative change in phosphorylation of AS at S328 and eNOS at S1179.
(B) Quantitation of densitometry represents the change in AS S328 and eNOS S1179
phosphorylation of treated lysates relative phosphorylation present in non-treated lysates,
n=3. GAPDH expression was used as loading control (not shown). Change in
phosphorylation of pS328 was near statistical significance (p<0.06). Change in S1179
phosphorylation was significant (n=3, * p<0.05) (C) DAN assay for NO production in
extracellular culture media showed a statistically significant decrease (n=3, * p<0.05 in
NO production in treated cells relative to non-treated cells.
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Figure 11. Free fatty acid (FFA) treatment of BAECs showed decreased phosphorylation
of AS at S328 and eNOS at S1179. BAECs were serum starved 16 hours then treated
with FFA or serum starve media alone for 1 hour. (A) Western showing relative change
in phosphorylation of AS at S328 and eNOS at S1179. (B) Quantitation of densitometry
represents the change in AS S328 and eNOS S1179 phosphorylation of treated lysates
relative phosphorylation present in non-treated lysates, n=5. GAPDH expression was
used as loading control (not shown). Changes in phosphorylation were significant (n=5,
*p<0.05) (C) DAN assay for NO production in extracellular culture media showed a
decrease in NO production in treated cells relative to non-treated cells, although the
change was not considered significant because of high variability.
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Figure 12. TNFα treatment of BAECs showed decreased phosphorylation of AS at S328
and eNOS at S1179. BAECs were serum starved 16 hours then treated with TNFα or
serum starve media alone for 1 hour. (A) Western showing relative change in
phosphorylation of AS at S328 and eNOS at S1179. (B) Quantitation of densitometry
represents the change in AS S328 and eNOS S1179 phosphorylation of treated lysates
relative phosphorylation present in non-treated lysates, n=3. GAPDH expression was
used as loading control (not shown). Changes in phosphorylation were significant (n=3, *
p<0.05) (C) DAN assay for NO production in extracellular culture media showed a
decrease in NO production in treated cells relative to non-treated cells, although high
variability prevented statistical significance.
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PART II: PKCα PHOSPHORYLATES A NOVEL ARGININOSUCCINATE
SYNTHASE SITE AT S328 DURING CALCIUM-DEPENDENT STIMULATION
OF ENDOTHELIAL NITRIC OXIDE SYNTHASE IN VASCULAR
ENDOTHELIAL CELLS1

Summary
Endothelial nitric oxide synthase (eNOS) utilizes L-arginine as its principal
substrate, converting it to L-citrulline and NO. L-citrulline is recycled to L-arginine by
two enzymes, argininosuccinate synthase (AS) and argininosuccinate lyase (AL),
providing the substrate arginine for eNOS and NO production in endothelial cells.
Together, these three enzymes, eNOS, AS and AL, make up the citrulline-NO cycle.
Although AS catalyzes the rate-limiting step in NO production, little is known about the
regulation of AS in endothelial cells beyond the level of transcription. In this report, we
showed that AS S328 phosphorylation was coordinately regulated with eNOS S1179
phosphorylation when bovine aortic endothelial cells (BAECs) were stimulated by either
a calcium ionophore or thapsigargin to produce NO. Furthermore, using in vitro kinase
assay, kinase inhibition studies, as well as PKCα knockdown experiments, we
demonstrate that the calcium-dependent phosphorylation of AS S328 is mediated by
PKCα. Collectively, these findings suggest that phosphorylation of AS at S328 is
regulated in accordance with the calcium-dependent regulation of eNOS under conditions

1
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that promote NO production, and are in keeping with the rate-limiting role of AS in the
citrulline-NO cycle of vascular endothelial cells.

Introduction
Nitric oxide (NO) production is strictly regulated in vascular endothelial cells.
Impairment of this control is associated with risk factors that compromise endothelial
function. Arginine directed to eNOS for purposes of NO production is maintained by the
recycling of citrulline to arginine, creating a distinct pool of arginine in endothelial cells
(1-4). This intracellular arginine pool that is sequestered from the bulk cytosolic arginine
is generated through the action of the arginine recycling enzymes argininosuccinate
synthase (AS) and argininosuccinate lyase (AL), where catalysis by AS is rate-limiting
for NO production in endothelial cells (5).

Since the endothelium represents a unique environment under the continuous
influence of signaling cascades that integrate responses to physiologic cues, it was logical
to propose that acute or immediate regulation of AS would be necessary to accommodate
regulatory responses already known for eNOS. For example, VEGF and insulin signaling
have been shown to coordinately regulate two phosphorylation sites of eNOS, increasing
phosphorylation at S1179 and decreasing phosphorylation at T497 to affect an overall
increase in eNOS activity (6). This change in eNOS phosphorylation that results from
either VEGF or insulin signaling is mediated largely by calcium-independent kinases,
such as Akt (7).
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Despite the fact that relatively recent reports have shown that AS is a
phosphophoprotein (8, 9), no physiologically relevant phosphorylation sites have been
reported. In 2008, an automated phosphoproteome analysis revealed that AS is
phosphorylated at serine 352 in HeLa cells, but the physiologic significance was not
established (9). Later that same year, Corbin et al also demonstrated that AS was a
phosphoprotein, and that VEGF stimulation of NO production affected the
phosphorylation of AS via a PKA pathway, but no phosphorylation site was identified
(8). In this report, we now show that phosphorylation of AS at serine 328 (S328) occurs
in response to the calcium-dependent activation of eNOS, and is mediated by PKCα.

Experimental Procedures
Cell culture
BAECs were isolated from whole bovine aorta as described in (10) with
modifications. Briefly, aortas were harvested, washed with PBS without magnesium or
calcium to remove blood, and lumenal surfaces were exposed by longitudinal dissection
followed by incubation with 0.1% collagenase for 10 minutes. Endothelial cell isolation
was achieved by rolling sterile swabs across surface, then releasing cells by twirling
swabs in 5ml enriched Dulbecco’s modified eagle medium (DMEM, 1g/L glucose,
Invitrogen) containing 10% FBS (HyClone) with 100 IU/ml penicillin and streptomycin
and 250 ng/ml amphotericin B (Cellgro) in 15 ml conical tubes. Cells were pelleted,
resuspended in 6ml DMEM + 10% FBS and plated in 25cm2 treated cell culture flasks.
Authentication of isolation of endothelial cells in culture was confirmed by flow
cytometry.
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Prior to treatment confluent BAEC (between passage 3 and 9) were serum starved
for 16 hours in DMEM (1g/L glucose, minus phenol red, Invitrogen) supplemented with
0.1% BSA and 1mM glutamine. Treatments included incubation with 100nM insulin
(Sigma), 100ng/ml VEGF (R & D Systems), 0.5µM calcium ionophore A23187 (Sigma),
10µM bradykinin (Sigma), 42µM rottlerin or 2.5µM bisindolylmaleimide I (Sigma) for
PKC inhibition, or 50µM BAPTA (Calbiochem). Incubation times are indicated in figure
legends. Controls were treated with serum starve media only

Generation of AS variants and transient transfections
AS cDNA was subcloned into pcDNA 3.1/ V5-His, B expression vector
(Invitrogen). The AS consruct was then subjected to site directed mutagenesis via the
QuikChange kit (Stratagene) per manufacturer’s instructions. Briefly, S328 was mutated
to alanine (A) to mimic a non-phosphorylated state and to aspartic acid (D) to mimic a
constitutively phosphorylated state. Primers used for S328A mutation were sense:
ACGGGTTTCTGGCACGCGCCCGAGTGTGAATTT and antisense:
AAATTCACACTCGGGCGCGTGCCAGAAACCCGT. Primers used for S328D
mutation were sense: ACGGGTTTCTGGCACGACCCCGAGTGTGAATTT and
antisense: AAATTCACACTCGGGGTCGTGCCAGAAACCCGT. Experimental
plasmids (1 μg DNA/well of a 6 well dish) were transiently transfected into BAEC using
Lipofectamine 2000 (Invitrogen) in serum free Opti-MEM I (Invitrogen). After 4 h,
media was replaced with DMEM containing 10% serum and cells were cultured for 6 or
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24 h. Cells were stimulated with calcium ionophore A23187 and sodium orthovanadate
for 4 hours then culture media was assayed for NO production via the DAN assay.

Mass spectrometry analysis
BAEC transiently transfected with AS were incubated 24 hours, serum starved for
16 hours, and treated with 10µM bradykinin or 50nM okadaic acid for 30 minutes.
Overexpressed AS was purified by its fused 6X-His tag using Ni-NTA agarose magnetic
beads (Qiagen). Proteins were separated by SDS-PAGE to identify the AS band (51 kD).
A duplicate gel was run to confirm expression of the AS plasmid by western blot. Gel
bands of interest were excised and destained. The protein disufides were reduced with
triscarboxyethylphosphine and the cysteines were alkylated with iodoacetamide. In-gel
trypsin digestion was used for proteolysis. Nanoflow reverse phase liquid
chromatography was used to separate the peptides by hydrophobicity (LC Packings,
Dionex, Sunnyvale, CA). Online detection was accomplished with an electrospray linear
ion trap mass spectrometer (LTQ, Thermo, San Jose, CA). Tandem mass spectra were
assigned to peptide sequences using Mascot and Sequest database search algorithms.
Sequence assignments were validated by manual inspection of the data.

Argininosuccinate synthase phosphoserine S328 specific antibody
A phospho-specific antibody against pS328 AS was generated by 21st Century
Biochemicals using the phospho-peptide AS sequence 322-335: RR-AhxYGFWH[pS]PECEFVR-amide. The phospho-AS antibody specificity was determined by
performing phospho-peptide competition of immunoprecipitations and western blotting.
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Western blot analysis
BAEC were lysed in RIPA buffer supplemented with protease and phosphatase
inhibitors (Pierce) followed by scraping for collection. Whole cell lysates were clarified
and total protein was quantitated using the BCA protein assay (Pierce). Equal amounts
(20µg) of protein were resolved on 4-15% Tris-HCl TGX precast gels (Bio-Rad) and
blotted onto Immobilon-P polyvinylidene difluoride membranes. Western blotting was
performed as previously described (11). Membranes were blocked in 100% Starting
Block (Pierce) and incubated with primary antibody, 1:2500 anti-AS (BD Transduction
Labs), in 20% Starting Block. Secondary antibody used was peroxidase-conjugated goat
anti-mouse or anti-rabbit IgG (Jackson ImmunoResearch Labs) at 1:50,000 dilution.
Blots were visualized by chemiluminescence using West Pico reagent (Pierce) and
exposed to film. Band intensities were quantitated using Quantity-One software (BioRad).

Nitric oxide determination
Nitrite was measured in the medium as an indicator of cellular NO using the
fluorescent 2,3-diaminonaphthalene (DAN) (Sigma) assay as described previously (12).
Reactions were carried out in 96 well black plates and fluorescence was read on a BMG
FLUOstar Galaxy spectrofluorometer platereader exciting at 360nm and detecting
emission at 405nm. Data are described as pmol nitrite per microgram protein.
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PKCα knockdown assay
BAEC, 90% confluent, were transfected for 48 hours with DsiRNA (dicersubstrate siRNA) directed against the 5th exon of PKCα (IDT) using lipofectamine 2000
(Invitrogen) performed as described previously for AS constructs. The duplex sequence
used to silence the gene expression was the following: 5'-rCrGrA rGrGrA rGrCrA
rArGrC rArCrA rArGrU rUrCrA rArGA T-3' 5'-rArUrC rUrUrG rArArC rUrUrG
rUrGrC rUrUrG rCrUrC rCrUrC rGrGrG-3'. Transfected BAEC were then treated with
calcium ionophore (A23187, Sigma) and lysed followed by western blotting. Relative
amounts of indicated proteins were quantitated as described above.

In vitro kinase assay
Assays were performed as described by Corbin et al. (8). Breifly, purified
recombinant AS was generated via subcloning bovine AS (NP_776317) into the pET28(c)+ vector (Novagen) and expressed in E. coli. The protein was subsequently purified
via the His-bind resin per the manufacturer’s instructions (Novagen). Successful
purification was verified by SDS-PAGE. The positive control used to determine kinase
activity for each kinase contained applicable peptide substrate, while negative control
contained all components except peptide. Addition of 33P-ATP to each reaction mixture
initiated the assays incubated at 30ºC for 30 minutes. Assay termination was achieved by
reaction spotting on phosphocellulose P81 plates followed by 3 washes then radioactivity
read via scintillation counting. Imaged in vitro kinase reactions were terminated by
addition of sample buffer then fractionated on 10% polyacrylamide gels.
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Results
Identification of the argininosuccinate synthase S328 phosphorylation site
In order to establish biologically significant sites of phosphorylation in the AS
sequence, we carried out a proteomic analyses by applying mass spectrometry (LCMS/MS) on overexpressed AS purified from cultured BAECs treated with bradykinin or
okadaic acid (PP2A and PP1 phosphatase inhibitor). Mass spectrometry analysis revealed
three highly conserved serine/threonine phosphorylation sites that were distinguished
from background ion signal. These included threonine 131 (T131)/ serine 134 (S134),
serine 180 (S180)/ serine 189 (S189), and serine 328 (S328) (Figure 1). The proximity of
T131 to S134 and S180 to S189 made these individual signals indistinguishable and
therefore described as T131/S134 and S180/S189.

Of the sites identified, S328 showed the greatest change in signal between cells
treated with phosphatase inhibitor (okadaic acid) and non-treated cells. In addition, S328
showed substantial change in signal with bradykinin treatment relative to non-treated
control cells (Figure 13). Furthermore, in silico modeling showed that the most accessible
sites for kinase interaction were T131/S134 and S328 while S180/S189 appeared buried
near the active site of the enzyme (Data not shown). Based on these results, S328 was
selected as being the strongest candidate for phosphorylation in vivo. Consequently, a
phospho-specific antibody directed against pS328 was developed for further investigation
(see EXPERIMENTAL PROCEDURES).
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Calcium-independent stimulation of BAECs decreases phosphorylation at S328
To determine whether phosphorylation at S328 had physiological significance,
changes in S328 phosphorylation were examined relative to treatment by physiological
cues that alter NO production. In particular, VEGF and insulin stimulation of NO
production were chosen for two reasons. First, there is evidence that AS phosphorylation
changed in response to VEGF treatment which was mediated via PKA signaling. (8).
Second, both VEGF and insulin are known to stimulate endothelial NO production by
promoting phosphorylation of S1179 of eNOS (13, 14).

As shown in Figure 14, and consistent with the literature (13), we found that
insulin and VEGF promoted an increase in phosphorylation by roughly 50% of eNOS at
S1179 (western Figure 14A,C; densitometry Figure 14B,D), with a corresponding
increase in NO production (Figure 14E). There was also concomitant decrease in
phosphorylation of eNOS at T497 by approximately 40% (western Figure 14A,C;
densitometry Figure 14B,D) (15-17). Surprisingly, phosphorylation at S328 was
markedly reduced by treatment with either VEGF (85%) or insulin (40%) (western Figure
14A,C; densitometry Figure 14B,D).

Calcium-dependent stimulation of BAECs increases phosphorylation at S328
Insulin and VEGF mediate eNOS phosphorylation at S1179 via the PI3K/Akt
pathway which is largely calcium-independent (18-20). Since calcium-independent
signaling mediated by either insulin or VEGF promoted the apparent dephosphorylation
of AS S328, we then questioned whether phosphorylation at S328 was involved with

85

calcium-dependent signaling. To initially explore this question, site-directed mutagenesis
analysis was carried out. Three constructs were used, one containing wild type AS, one
containing an alanine substitution for S328 (phospho-null), and one containing an
aspartate substitution for S328 (phospho-mimetic). As shown in Figure 15A, the
overexpression of the phospho-mimetic S328D AS or wild type AS (WT) led to a twofold increase in NO production relative to overexpressed S328A when stimulated with
calcium ionophore and sodium orthovanadate. Consistent expression of the constructs is
shown by western blotting (Figure 15B). The observation that WT and S328D gave a
similar response in NO production may imply that WT is phosphorylated endogenously
at S328 in response to this treatment as well.

Since these findings were consistent with a calcium-dependency, experiments
were then carried out to determine whether calcium-dependent changes in S328 could be
demonstrated for endogenous AS. For these experiments, BAECs were treated with either
the calcium ionophore, A23187, or the endoplasmic reticulum ATPase inhibitor,
thapsigargin. Both agents are known to promote an intracellular increase in calcium (21)
and stimulate NO production. As shown in Figures 4A and 4B, treatment with either
agent promoted phosphorylation of eNOS at S1179 by nearly 50% with a subsequent
decrease in phosphorylation of eNOS at T497 by 40%, consistent with reported values
(21, 22). However, in this case, treatment with calcium ionophore or thapsigargin
demonstrated an increase in phosphorylation at AS S328 (~60%) (Figure 16A,B).
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To further substantiate the calcium dependency of AS S328 phosphorylation,
BAECs were treated with the intracellular calcium chelator BAPTA-AM. As expected,
calcium ionophore and thapsigargin rescued phosphorylation at eNOS pS1179 that
diminished with BAPTA-AM treatment alone. Importantly, as shown in Figure 16A,
treatment with 50 µM BAPTA-AM completely abolished phosphorylation at S328, as
well as the phosphorylation at eNOS S1179. Thus, phosphorylation of AS S328 appeared
to be coordinately regulated with the phosphorylation of eNOS S1179 through calciumdependent signaling.

To demonstrate physiological relevance, NO measurements were taken after cells
were treated with BAPTA-AM for 30 minutes followed by stimulation with calcium
ionophore A23187 for 20 minutes. A23187 and thapsigargin significantly increased NO
production relative to non-treated or BAPTA-AM treated BAECs (Figure 16C). In
addition, BAPTA-AM treatment significantly decreased A23187 or thapsigargin
stimulated NO production by 2.5 and 2-fold respectively.

PKC is involved in mediating S328 phosphorylation in BAECs
In order to further elucidate the signaling pathway involved in the calciumdependent phosphorylation of AS at S328, a series of experiments were carried out using
kinase inhibitors. Since the classical protein kinase C (PKC) isotypes are calciumdependent kinases and are not involved in insulin or VEGF signaling (23, 24), we
hypothesized that a member of the PKC family may be involved in the calciumdependent phosphorylation of AS S328. To test this hypothesis, non-isotype specific
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PKC inhibition studies were carried out. As a first approach, the effects of PKC inhibition
were directly measured by examining AS S328 phosphorylation. As shown in Figure 17A
and B, treatment of BAECs with either the PKC inhibitor rottlerin or bisindolylmaleimide
I, followed by stimulation with calcium ionophore, decreased AS S328 phosphorylation
by approximately 60% relative to non-treated controls. These results were taken to be
consistent and supportive of the role of a classical PKC isotype promoting
phosphorylation of AS at S328.

Interestingly, phosphorylation at T497 or S1179 of eNOS also decreased with
treatment of rottlerin by approximately 60%, irrespective of calcium stimulation. In
contrast, when BAECS were treated with bisindolylmaleimide I alone, phosphorylation at
S1179 and T497 of eNOS decreased by only 20%. However, upon calcium stimulation,
phosphorylation at eNOS S1179 increased to levels similar to calcium ionophore
treatment alone. Nevertheless, phosphorylation at S328 was unaffected by calcium in
presence of bisindolylmaleimide I (Figure 17A).

In order to demonstrate physiological relevance of the system in response to
inhibitors, we measured NO production for each treatment (Figure 17C). PKC inhibition
with bisindolylmaleimide I has little effect on NO production by BAECs, however
rottlerin significantly reduced calcium ionophore stimulated NO production by over 2fold. These results suggest that rottlerin may affect the activity of several kinases, and
bisindolylmaleimide I clearly decreased phosphorylation at eNOS T497 and thus
promoted NO production similar to calcium ionophore alone.
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To further examine the potential involvement of other calcium-dependent kinases
that could phosphorylate S328, additional kinase inhibition studies were carried out.
ERK1/2 was inhibited with PD 98059 and CaMKII was inhibited with KN93. In either
case, no inhibitor effect was observed on AS S328 phosphorylation when BAECs were
co-treated with calcium ionophore or thapsigargin (data not shown). These results suggest
that PKC, but not ERK1/2 or CaMKII, is responsible for the calcium stimulated
phosphorylation of AS S328.

Since the α isotype of PKC (PKCα) is a calcium-dependent kinase that has been
shown to be active during calcium-dependent stimulation of eNOS (25), we sought to
determine whether this is the isotype responsible for phosphorylating S328 of AS. To test
this, we examined the effects of direct knockdown of PKCα with dicer substrate siRNA
(DsiRNA). DsiRNA is different from traditional siRNA used for gene silencing in that
the RNA duplex used to silence not only mimics dicer products, but is also optimized for
dicer processing by the RISC complex to result in a more potent knockdown (26). As
shown in Figure 18, significant knockdown of PKCα was achieved. DsiRNA directed
against PKCα allowed for 50% and 75% knockdown at 1nM and 5nM DsiRNA,
respectively. Knockdown of PKCα followed by treatment with calcium ionophore
showed a decrease in phosphorylation of S328 by 50% and 60% with 1nM or 5nM,
respectively, and prevented increased phosphorylation in response to calcium ionophore
treatment. Phosphorylation of eNOS at S1179 was largely unaffected by PKCα
knockdown under these conditions, while eNOS T497 dropped approximately 60% when
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PKCα was knocked down by 80%. These results suggest that PKCα is a kinase that
phosphorylates S328 of AS.

PKCα directly phosphorylates AS
Since an observed decrease in phosphorylation due to kinase knockdown may be
the result of inhibition of an upstream kinase in a signaling cascade, a targeted in vitro
kinase assay was performed to determine whether PKCα directly phosphorylates AS.
Akt1 was used as a negative control based on the lack of a consensus Akt
phosphorylation motif (R-X-R-X-X-S/T) (27) in the AS protein sequence.

As shown in Figure 19A, PKCα clearly demonstrated the capacity to
phosphorylate AS in vitro. Although there was an increase in counts above the blank
reaction with Akt1, this was below the threshold considered significant. SDS-PAGE
fractionation of [32P]-labeled kinase reaction products and visualization by
autoradiography film exposure confirmed that PKCα, but not Akt1, phosphorylates AS
(Figure 19B).

Discussion
NO production is a dynamic and targeted process, and multi-level regulation of
eNOS is well established (28) to control this process. Since AS is required for NO
production, it was logical to speculate that post-translational regulation of AS would play
a significant role in maintaining NO homeostasis. Indeed, recent work using mass
spectrometry analysis has shown that AS is phosphorylated at site S352 (human
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sequence) (9); however, the biological significance of the phosphorylation at serine 352
was not defined. In addition, Corbin et al (8) showed that phosphorylation of AS was
changed in response to VEGF treatment, nevertheless the phosphorylation site was
unknown. In this report, we demonstrate that AS S328 phosphorylation relates to the
calcium-dependent stimulation of NO production, and is mediated by PKCα (see working
model, Figure 20).

During calcium-dependent NO production, increased intracellular calcium
stimulates eNOS activity through the activation of calmodulin and subsequent
displacement of eNOS from caveolin at the plasma membrane, as well as through several
post-translational events, which include phosphorylation at S1179 of eNOS (29).
Although a varied assortment of kinases have been shown to phosphorylate eNOS at
S1179, including PKA, AMPK, CaMKII, Akt, PKG, and PKCα, CaMKII is the
prominent kinase that promotes activation under calcium-dependent conditions (28, 30).
Moreover, CaMKII is more sensitive to calcium stimulated activity than PKCα (31). This
may account for the disparity in recovery of phosphorylation of eNOS S1179 and AS
S328 that was observed after A23187 treatment following chelation with BAPTA-AM
(Figure 15).

Although somewhat contentious, there is a growing body of evidence that
suggests that the calcium-dependent kinase PKCα is active during calcium-mediated
eNOS stimulation (25, 32, 33). This is in contrast to the calcium-dependent activation of
PKCβ that was shown to decrease eNOS activity through phosphorylation of T497 (34-
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36), suggesting that different isoforms of PKC may impart different effects in the NO
production pathway. The involvement of different isotypes of PKC may also explain the
distinct phosphorylation pattern of AS at S328 from eNOS at T497 in response to
treatment (Figure 16 and 18). Thus, the contrasting pattern of phosphorylation between
AS S328, eNOS S1179 and T497 under different treatments with calcium ionophore,
calcium chelation, and PKC inhibitors was taken to indicate that unique calciumdependent kinases participate in phosphorylating these respective sites.

eNOS is also positively regulated in a calcium-independent fashion through
activation of the PI3K/ AKT pathway which is stimulated by factors such as vascular
endothelial growth factor (VEGF) and insulin (37). In fact, the observation that calciumindependent activation of eNOS was associated with a decrease in phosphorylation at
S328 further supports the involvement of AS regulation at S328 in the calcium mediated
arm of eNOS dependent NO production (Figure 13). Indeed, several reports have shown
that stimulating PKCα blunts the effects of VEGF or insulin (23, 24). This relationship
between PKCα and calcium-independent signaling may explain the observed increase in
S328 phosphorylation with agents that stimulate PKCα activity, while insulin or VEGF
decrease S328 phosphorylation. Although the precise role of PKC activation in NO
production is unsettled (25, 38), in this report, we show PKCα supports NO production
through the phosphorylation of AS at S328. Because, previous work had shown that
overall phosphorylation of AS increased in response to VEGF treatment, this suggests
that other sites of phosphorylation are involved in regulating AS as the result of calciumindependent signaling.
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Considering the critical role AS plays in NO production and the spatial and
temporal manner that eNOS is regulated by calcium levels, it is not surprising that AS is
susceptible to a regulatory mechanism governed by changes in calcium. Previously, our
laboratory demonstrated that AS resides in caveolae with eNOS under conditions that
stimulate NO production, such as stimulation with bradykinin (39). Since PKCα is
associated with the plasma membrane when activated (40), a functional relationship
between PKCα and AS may be supported. Furthermore, it has been previously reported
that changes in intracellular calcium alter the subcellular localization of eNOS (41).
Therefore, it is tempting to speculate that the phosphorylation of AS at S328 may change
AS localization in a manner similar to the altered localization of eNOS in response to
calcium mediated signaling. Experiments are underway to test this hypothesis.

These results overall represent the first demonstration of a biologically relevant
phosphorylation site for AS, and are consistent with previous findings demonstrating the
coordinate regulation of eNOS and AS relative to vascular endothelial NO production.
Given the central role of endothelial NO production in vascular health, future studies, to
fully characterize the biologically relevant AS phospho-sites, merits further
consideration.
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Figure 13. S328 is an exposed site accessible by kinases and shows change in
phosphorylation relative to treatment. BAECs were transiently transfected with AS
expression vector then treated with 10µM bradykinin or 50nM okadaic acid. AS was Histag purified then subjected to SDS-PAGE. The band corresponding to AS was excised
and trypsin digested before tandem mass spectrometry analysis. Results represent one
experiment with samples analyzed in triplicate with SE represented by error bars.
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Figure 14. Calcium-independent stimulation of NO production decreased
phosphorylation at argininosuccinate synthase S328. BAECs were treated with insulin at
100nM (A) or VEGF at 100 ng/mL (C) for 20 min. Phosphorylation was assayed by
Western blotting using phospho-specific antibodies and reprobed with eNOS and AS
specific antibodies. Blots are representative of 3 separate experiments. Densitometric
values (B and D) represent percent change from non-treated (NT) controls normalized to
total eNOS or AS respectively. Densitometric changes are significant with SE
represented by error bars (n=3, p< 0.05). (E) Culture media from BAECs treated with
insulin or VEGF was assayed for nitrite with the DAN assay with SE represented by error
bars (* n=3, p<0.05).
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Figure 15. Overexpressed S328 phospho-null mutation to alanine produced significantly
less stimulated NO than wild type (WT) or phospho-mimetic (S328D). (A) BAECs were
transiently transfected with wild type (WT), phospho-null serine to alanine 328 (S328A),
or phospho-mimetic serine to aspartate (S328D) AS then stimulated with 0.5µM calcium
ionophore A23187 and 50µM sodium orthovanadate. Results are representative of 4
different experiments with SE noted by error bars. (* p<0.05 relative to WT; † p<0.05
relative to S328D). (B) Representative western blot confirming WT, S328A, and S328D
overexpression.
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Figure 16. Calcium-dependent stimulation of NO production increased phosphorylation
at argininosuccinate synthase S328. (A) Western blot analysis of changes in
phosphorylation relative to 20 minute treatment with calcium ionophore (A23187),
thapsigargin (Thap), in presence or absence of intracellular calcium chelator BAPTAAM. Blots are representative of 5 separate experiments. (B) Densitometric values
represent percent change from non-treated (NT) controls normalized to total eNOS or AS
respectively. Densitometric changes are significant with SE represented by error bars. (C)
Culture media from BAECs treated with calcium ionophore (A23187), thapsigargin
(Thap) in presence or absence of BAPTA-AM was assayed for nitrite with the DAN
assay. (n=5, significantly increased from NT * , p<0.05, significantly decreased from
A23187 alone ‡ p<0.05, significantly decreased from Thap alone † p<0.05).
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Figure 17. Non-isotype specific inhibition of PKC with 42µM rottlerin or 2.5µM
bisindolylmaleimide I decreased phosphorylation at AS S328. BAECs were pre-treated
with 42µM rottlerin (Rott) or 2.5µM bisindolylmaleimide I (Bis) for 30 minutes prior to
stimulation with calcium ionophore (A23187) for 20 minutes. (A) Representative western
blot of 3 experiments. (B) Densitometric values represent percent change from nontreated (NT) controls normalized to total eNOS or AS respectively. Densitometric
changes are significant with SE represented by error bars (n=3, p< 0.05). (C) Culture
media from treated BAECs was assayed for nitrite with the DAN assay. A23187
significantly increased NO production with or without bisindolylmaleimide I
(significance relative to NT: * n=3, p<0.05; significance relative to A23187: ‡ n=3,
p<0.05).
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Figure 18. Knockdown of PKCα decreased phosphorylation at S328 but not eNOS
S1179. BAECs were treated with 1nM or 5nM dicer substrate RNA (DsiRNA) directed
against the 5th exon of PKCα and allowed to express for 24 hours, followed by
stimulation with calcium ionophore A23187 for 20 minutes and compared to non-treated
(NT) BAECs. (A) Representative western blot of 3 experiments. (B) Densitometric
values represent percent change from non-treated (NT) controls normalized to total eNOS
or AS respectively. Densitometric changes are significant (except for A2317 effect on
PKCα expression or 1nM DsiRNA treatment on pS1179 eNOS) with SE represented by
error bars (n=3, p< 0.05). (C) Culture media from treated BAECs was assayed for nitrite
using the DAN assay (significance relative to NT or DsiRNA alone: * n=3, p<0.05)
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Figure 19. PKCα, but not Akt phosphorylate AS in vitro. (A) In vitro kinase assays. Gray
bars represent the incubation of purified AS minus kinase (Blank). Black bars represent
the incubation of purified AS with the indicated kinase (Kinase). Kinase activity is
represented as counts per minute (CPM) with error bars representing SE (n = 3*, p <
0.05). (B) Representative autoradiograph of in vitro kinase reactions separated by SDSPAGE as described in (A).
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Figure 20. Working model demonstrating phosphorylation events in response to calciumindependent (left) or calcium-dependent (right) signaling. (Left) Calcium-independent
stimulation of eNOS (such as with insulin or VEGF) leads to signaling events that result
in dephosphorylation of AS. Insulin stimulation activates Akt which phosphorylates
eNOS at S1179; activation of eNOS noted by arrow pointing to NO. The observed
decrease in phosphorylation of AS at S328 is likely mediated by a phosphatase (“p-tase”).
(Right) Calcium-dependent stimulation of eNOS (such as with calcium ionophore or
thapsigargin) leads to the activation of PKCα and phosphorylation of AS at S328. The
increase in calcium also activates a number of kinases that can phosphorylate eNOS at
S1179 (noted by “kinase”) leading to the activation of eNOS and subsequent production
of NO.
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PART III: CALCIUM-DEPENDENT STIMULATION OF NITRIC OXIDE
PRODUCTION LEADS TO CYTOSOLIC CO-LOCALIZATION OF
ARGININOSUCCINATE SYNTHASE AND ENDOTHELIAL NITRIC OXIDE
SYNTHASE IN BOVINE AORTIC ENDOTHELIAL CELLS

Summary
Argininosuccinate synthase (AS) catalyzes the rate limiting step in the arginine
recycling that is required for nitric oxide (NO) homeostasis in endothelial cells. Coregulation of AS and endothelial nitric oxide synthase (eNOS) phosphorylation has been
demonstrated in reponse to calcium mediated stimulation of eNOS in bovine aortic
endothelial cells (BAECs), although the function of AS phosphorylation at S328 (pS328)
was not identified. In this report, by utilizing immunofluorescent confocal microscopy,
we show that phosphorylation of S328 promotes cytosolic localization of AS.
Furthermore, with membrane enrichment studies, we show that the phospho-mimetic
mutant S328D AS and endogenous pS328 AS are found only in the cytosol and not
associated with plasma membrane proteins. Moreover, cytosolic co-localization of eNOS
and pS328 AS was demonstrated in response to calcium stimulation of BAECs. These
results suggest that regulation at S328 promotes cytosolic localization of AS in order to
provide cytosolic eNOS with substrate.
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Introduction
Argininosuccinate synthase (AS) is a homotetrameric ATPase that is essential in
the production of the potent vasodilator endothelial nitric oxide (NO) (1). AS and
argininosuccinate lyase (AL) are responsible for converting citrulline and aspartate to
arginine, a process termed arginine recycling (2). Arginine recycling and AS expression
are critical in maintaining levels of the endothelial nitric oxide synthase (eNOS) substrate
arginine (1, 3). In addition to NO, eNOS produces the citrulline that serves as substrate
for AS (4). Therefore, the cycling of citrulline to NO production in endothelial cells is
known as the citrulline-NO cycle (5). Importantly, AS catalyzes the rate-limiting step of
the arginine recycling required for the citrulline-NO cycle to maintain endothelial NO
homeostasis (6).

With regards to citrulline-NO cycle regulation, several mechanisms specific to
eNOS regulation have been defined (7). An important mode of eNOS regulation occurs
by modulating eNOS cellular localization or compartmentalization (8). This spatial
regulation of eNOS is mediated, in part, through protein-protein interaction with
caveolin-1 (9). Caveolin-1 forms high molecular weight oligomers of > 350 kDa that give
rise to flask-shaped signaling platforms called caveolae at the plasma membrane (10).
Caveolin-1 interaction with eNOS inhibits NO production by interfering with eNOS
association with calcium dependent calmodulin (CaM), a required event for NO
production (11). Three predicted consensus caveolin binding motifs have been identified:
ɸXɸXXXXɸ, ɸXXXXɸXXɸ, ɸXɸXXXXɸXXɸ, where ɸ is any aromatic amino acid
tryptophan, tyrosine, or phenylalanine, and X is any amino acid (12). The interaction of
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eNOS with caveolin-1 occurs by way of the eNOS caveolin binding motif ɸXXXXɸXXɸ
(amino acids 350-358) associating with caveolin-1 at amino acids 82-101 (13). As a
result, dissociation of eNOS from plasma membrane caveolin-1 increases eNOS activity.
Interestingly, a putative caveolin binding motif ɸXXXXɸXXɸ (bovine sequence 317325) has also been identified in the AS amino acid sequence (Corbin et al, unpublished),
as well as a phosphorylation site at S328, 3 amino acids away from the putative caveolin
binding motif. It is currently unknown whether AS associates with caveolin, or if the
phosphorylation at S328 regulates the potential association.

Since eNOS dissociation with caveolin-1 promotes eNOS activity, some
stimulators of NO production, such as bradykinin and calcium ionophore, mediate eNOS
stimulation, in part, by promoting eNOS cytosolic localization (14-16). Bradykinin and
calcium ionophore are factors that rely on calcium-dependent stimulation of eNOS.
Interestingly, calcium-independent activation of eNOS with agents such as insulin or
VEGF promotes plasma membrane localization of eNOS (17, 18). Under those
circumstances, eNOS palmitoylation allows plasma membrane localization without
caveolin-1 interference of activity (19). Consequently, regulation of eNOS localization
allows NO production to be targeted to particular sub cellular regions (20). Considering
that AS is a key component of the citrulline-NO cycle, it is logical that AS regulation
would occur coordinately with eNOS in response to these factors. Indeed, it has been
recently reported that AS phosphorylation at S328 is co-regulated with eNOS S1179
(eNOS activating phosphorylation) in response to calcium-dependent stimulation of
eNOS in bovine aortic endothelial cells (BAECs) (see Part I and II). Taking these
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observations together, we hypothesized that the calcium-dependent AS phosphorylation
at S328 promotes cytosolic localization of AS in a coordinate fashion with eNOS.

Experimental Procedures
Bovine aortic endothelial cell isolation
Isolation was performed as described by Schwartz (21) with modifications. Whole
bovine aortae were obtained within 15 minutes of slaughter from Central Beef Industries,
LLC (Center Hill, Fl). Aortae were transferred to ice cold isotonic PBS without calcium
or magnesium and transported to the laboratory on ice. Growing media (20% FBS, 2 mM
glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin in Dulbecco’s Modified
Eagle’s Medium (DMEM) with 1 g/L glucose) was prepared and 100 ml was heated to
37ºC and 100 ml cooled to 4ºC. Isolation of endothelial cells occurred within 2 hours of
sacrifice. First, excess connective tissue and fat was removed from the exterior of the
ascending aorta, followed by excess artery removal with a sterile #22 blade scalpel. The
vessel was then opened longitudinally to expose aortic lumen followed by 5 washes with
ice cold PBS with 100 U/ml penicillin and 100 mg/ml streptomycin. The rinsed vessel
was stored in ice cold PBS while the remaining 5 vessels were processed as described.
After all aortae were processed, cut aorta were individually laid in Petri dish with lumen
side up, followed by adding drops of 0.1% collagenase on exposed lumen and allowed to
incubate 10 minutes at room temperature. Sterile swabs soaked with 4ºC growing media
were used to isolate endothelial cells from the lumen of the collagenase treated vessel
with a stroke and twist motion, ensuring not to overlap an area twice. Cells were
dislodged from swabs in 5 ml growing media (4ºC) in a 15 ml conical, then centrifuged at
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4ºC for 7 minutes at 1000 RPM. Supernatants were discarded and pellet was resuspended
in 6 ml 37ºC and plated in 25 cm culture flasks overnight at 37ºC and 5% CO2. This
process was repeated for remaining 5 aortae. Cells were rinsed with PBS and re-fed
growing media every 2 days until cells reached confluence, then individual culture flasks
were subcultured into 3, 225 ml flasks. Once cells reached confluence, each flask was
trypsinized and resuspended in cryopreservation media (growing media with 10%
DMSO) followed by aliquoting into 6 cryovials and stored at -80ºC for future use.
Endothelial cell authentication was achieved by flow cytometry.

Cell culture
Cryovials were retrieved from -80ºC and thawed to 37ºC then cells were
resuspended in 12 ml culture media (10% FBS, 100 U/ml penicillin and 100 mg/ml
streptomycin, in DMEM with 1 g/L glucose) in 75 cm flask and allowed to grow to
confluence. Cells between passage 3 and 8 were then subcultured into 15 cm diameter
culture dishes (Corning) for membrane analysis or immunoprecipitation, or 8 well culture
slides (BD Falcon), for immunofluorescent confocal microscopy. All cells were serum
starved for 16 hours prior to15 minute treatment with either 0.5 µM calcium ionophore
A23187 (Sigma) or 100 nM insulin (Sigma).

Generation of AS plasmid
RNA was isolated from BAECs then subjected to reverse transcription with
random primers to generate a population of random cDNA. Primers specific to AS were
used to amplify AS cDNA via polymerase chain reaction (PCR). PCR products were
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analyzed by agarose gel electrophoresis to ensure AS cDNA amplification, then removal
of dNTPs, unwanted cDNA, and buffer components was achieved with the Qiagen PCR
clean up kit. Purified PCR product and V5/ 6X His, carbenicillin resistance encoding
plasmid (pcDNA3.1/ V5 His B) was then restriction digested with Eco RI and Bam H1
followed by agarose gel electrophoresis, purification of fragments from agarose (Qiagen
agarose gel purification kit “QiaQuick”), and DNA quantitation. T4 ligase was added to
100 ng of purified vector was and 8.5 ng AS insert and allowed to incubate at 37ºC for 1
hour for ligation of AS cDNA to V5/ 6X His plasmid in an orientation that placed V5 and
His tags at the C-terminus. Ligation product was used to transform competent E. coli with
the heat shock technique, and cultures were allowed to grow overnight at 37ºC in 100
µg/ml carbenicillin containing LB broth for plasmid amplification. Each culture was
restriction digested and analyzed by agarose gel electrophoresis to ensure plasmid
amplification took place. Positive cultures were then plated on LB/ carbenicillin plates
and allowed to grow at 37ºC overnight. CFU selection was based on demonstration of
antibiotic resistance, and isolated colonies were subcultured into 250 ml LB broth with
carbenicillin and allowed to incubate overnight at 37ºC. E. coli was then pelleted and
plasmid isolation was achieved using the maxi-prep plasmid purification kit (Sigma).
Isolated plasmid was ethanol precipitated for further removal of contaminants, then
quantitated via spectrophotometry. Plasmid preps were sequenced to confirm the
presence of AS insert (GeneWiz).
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Site-directed mutagenesis and transient transfection
Mutagenesis at S328 of AS was achieved with the QuikChange mutagenesis kit
(Stratagene). Forward and reverse primers were designed to contain the desired mutation
in addition to sequence flanking the site of interest. Therefore, for a phospho-null
mutation at S328, primers encoding alanine in place of serine were generated, and
aspartate for S328 for phospho-mimetic. Primers used for S328A mutation were sense:
ACGGGTTTCTGGCACGCGCCCGAGTGTGAATTT and antisense:
AAATTCACACTCGGGCGCGTGCCAGAAACCCGT. Primers used for S328D
mutation were sense: ACGGGTTTCTGGCACGACCCCGAGTGTGAATTT and
antisense: AAATTCACACTCGGGGTCGTGCCAGAAACCCGT. Purified plasmid,
primers, dNTPs, reaction buffer, and Pfu polymerase were mixed then placed in a
thermocycler for PCR. Pfu polymerase is used in this reaction because of its high fidelity
and increased thermostability. Mutated constructs were sequenced for confirmation of
mutagenesis (GeneWiz).

For transfection, subconfluent BAECs grown in 15 cm culture dishes were
transiently transfected with either wild type (WT), S328A, or S328D AS constructs.
Lipofectamine 2000 (462 µl) was mixed with reduced serum media Opti-Mem (14.4 ml)
(Invitrogen) and allowed to incubate at RT for 5 minutes. Plasmid DNA was diluted to
the same concentration then 17 µg of each plasmid was added to 4.8 ml Opti-Mem.
Lipofectamine/ Opti-Mem mixture (4.8 ml) was added to each aliquot of diluted DNA
and allowed to incubate 20 minutes. Media of BAECs in 15 cm culture plates was
exchanged to 25 ml transfection media (1 g/L glucose DMEM, 10% FBS), then 4.6 ml of
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each DNA mixture was added to respective dishes and allowed to incubate at 37ºC in 5%
CO2 for 4 hours. Cells were washed with PBS then 25 ml fresh 37ºC transfection media
was added to each plate. Cells were allowed to express transfected plasmid overnight
before further analysis. For BAEC transfection on 8-well culture slides, the same
procedure was performed with reagent volumes reduced to area equivalents.

Immunofluorescence and confocal microscopy
Cultured cells between passage 3 and 6 were grown to subconfluence on 8-well
treated culture slides, then serum starved overnight for experiments where cells were
treated with calcium ionophore or insulin. For transfection experiments, cells were
transfected as described above then subjected to immunofluorescence the following day.
On day of immunofluorescence, slides were washed with isotonic PBS 2 times to remove
media then fixed in 3.7% paraformaldahyde at 37ºC and 5% CO2 for 15 minutes. Cells
were washed 2 times for 5 minutes each with PBS, then permeabilized with 0.1% Triton
X at RT for 10 minutes. Slides were washed as before, then blocked with 10% normal
goat serum (Invitrogen) for 30 minutes. Primary antibodies directed against pS328 AS
(rabbit), V5 (mouse, Invitrogen), or eNOS (mouse, BD Transduction Laboratories) were
added to indicated wells (1/100 dilution in 10% normal goat serum) and allowed to
incubate 1 hour. Buffer was removed then cells were washed 3 times for 5 minutes each
with PBS. Secondary antibodies (goat anti-rabbit Alexa 488 and goat anti-mouse Alexa
594) at 1/1000 in 10% normal goat serum were added and allowed to incubate 1 hour.
Cells were washed 3 times at 5 minutes each with PBS then wells were removed, and
DAPI nuclei stain with anti-fade reagent was added. Slides were topped with a cover slip
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then sealed with Hard as Nails clear fingernail polish (Sally Hansen) and frozen at -20ºC
until analysis at confocal microscopy core the following day. Cells were viewed at 60X
oil immersion with an Olympus FV1000 MPE multiphoton laser scanning microscope
(USF Microscopy Core). Images were analyzed qualitatively for membrane localization
or co-localization of pS328 AS and eNOS represented by yellow. Observed interactions
or localizations were confirmed with membrane enrichment techniques or
immunoprecipitation.

Conconavalin A membrane protein enrichment
To isolate membrane components for analysis of associated proteins, the
concanavalin A (Con A) technique from Lee et al was used(22), where conjugated
magnetic beads were utilized to sequester plasma membranes from lysed BAECs. For
conjugation, streptavidin coated beads were washed then resuspended in TBS followed
by the addition of biotinylated Con A to resuspended magnetic beads and allowed to
incubate with agitation for 1 hour.. Beads were then washed to remove unbound Con A
then resuspended in TBS for future use. BAECs were grown to confluence as described
above then collected in ice cold TBS by scraping. Cells were washed then resuspended in
TBS with protease and phosphatase inhibitors (Pierce). Lysis of cells was achieved by
sonication at 80 W in 4, 10 second bursts with 20 second break between bursts with tubes
on ice. Lysate was then added to prepared beads and allowed to incubate for 1 hour with
rotisserie agitation. After incubation, beads were pelleted with a magnet then unbound
supernatant was collected and considered the cytosolic fraction. Beads were washed with
ice cold TBS 4 times with beads transferred to new tube at the third wash. To elute bound
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proteins, 75 µl elution buffer (0.25 M methyl α-D glucoside, 0.5% CHAPS, and protease/
phosphatase inhibitor cocktail in TBS) was added to beads then pelleted with magnet,
then elution was repeated and elutions were combined. Analysis of eluted proteins was
performed by western blot (see Part I, page 31 for western protocol).

Membrane protein solubilization with organic solvents
In order to solubilize membrane components and their associated proteins,
membrane fractions were subjected to further solubilization with the Mem-PER kit
(Pierce) which utilizes organic solvents to solubilize hydrophobic proteins found in the
membrane. First, BAECs transfected with WT, S328A, or S328D AS, or no transfection
were lysed with RIPA lysis buffer. Lysates were centrifuged at 4ºC for 15 minutes at
15,000 RPM then supernatants were removed. The insoluble pellet was washed with PBS
then reagents A, B, and C were added to the pellet as described by the manufacturer
followed by incubation of tubes on ice for 30 minutes with vortexing every 5 minutes.
Tubes were centrifuged at 10,000 X g for 3 minutes and supernatants were transferred to
new tubes. The remaining procedure for separating hydrophobic from hydrophilic
proteins was not performed because the objective was only to solubilize the insoluble
fraction. The solubilized proteins were resolved via SDS-PAGE and analyzed by western
blotting.

Immunoprecipitation
Selected antibodies (rabbit polyclonal anti-eNOS, BD Transduction Laboratories;
or goat polyclonal anti-AS, AbCam) were conjugated to magnetic beads using M270
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Epoxy (Invitrogen) and stored at 4ºC less than 2 days prior to immunoprecipitation. Cells
were grown in 15 cm diameter dishes to subconfluence as described above prior to either
100 nM insulin treatment or transfection. First, media was removed and cells were
washed 2 times with ice cold PBS. Cells were lysed by 30 minute incubation with
agitation in low detergent RIPA buffer (150 mM sodium chloride, 1% NP-40, 50 mM
Tris at pH 8.0, 0.1% Brij 35, and protease and phosphatase inhibitor cocktail) then
scraped into 2 ml tubes and centrifuged at 15,000 RPM at 4ºC for 15 minutes to remove
insoluble material. BCA protein assay (Pierce) was performed to assess protein
concentration of supernatants, then 2 mg protein from insulin treated lysates or nontreated lysates was added to anti-eNOS conjugated magnetic beads, or 2 mg protein from
lysates of transfected BAECs was added to anti-AS conjugated magnetic beads and
allowed to incubate on rotisserie mixer overnight at 4ºC. The following day, beads were
pelleted and washed with low detergent RIPA buffer 4 times. Bound proteins were eluted
with an acidic elution buffer (Invitrogen) then analyzed by western blot (see Part I, page
31 for western blot procedure).

Endogenous AS silencing and mutant AS overexpression
To knockdown endogenous AS, siRNA directed against AS at nucleotides 73-94
with the sequence 5’-AAGGAGCAAGGCTATGACGTCATTGCC- 3’ was used as
described by (1). S328A, S328D and WT AS constructs were mutated with silent
mutations (SM) at nucleotides 81 and 84 region with the forward primer 5'
CTCGTGTGGCTGAAGGAGCAGGGATATGACGTCATTGCCTACC 3’ and reverse
primer 5’ GGTAGGCAATGACGTCATATCCCTGCTCCTTCAGCCACACGAG 3’
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using the QuikChange kit (Stratagene) as described above. Co-transfection of siRNA and
S328A-SM, S328D-SM, or WT-SM AS in BAECs grown to subconfluence in 12-well
plates was performed as described above, then cells were allowed to express siRNA and
AS constructs for 48 hours. Media was exchanged to arginine and serum free media (1
g/L glucose DMEM without phenol red, arginine, leucine, lysine, or sodium pyruvate
(Sigma), replenished with citrulline and all removed components except arginine)
supplemented with 0.1% BSA and allowed to arginine starve for 2 hours. Cells were then
given fresh arginine free media and allowed to incubate overnight at 37ºC and 5% CO2.
After 16 hours, media aliquots were taken for NO determination with the DAN assay (see
Part I page 35 for DAN assay procedure).

Results
Redistribution of AS occurs as a result of S328 mutation
In a previous study, we established that increased intracellular calcium leads to
S328 phosphorylation (see Part II). Since eNOS translocates to the cytosol upon calcium
stimulation, we sought to determine whether regulation of AS at S328 leads to altered
subcellular localization as well. Therefore, we used site-directed mutagenesis to mutate
S328 to phospho-mimetic aspartate (S328D) or alanine for a phospho-null mutation
(S328A) from a V5 tagged plasmid containing non-mutated AS (WT) for overexpression
in BAECs. We then performed immunofluorescent confocal microscopy using anti-V5
antibody to observe changes in localization of AS relative to the mutation. As shown in
Figure 21, non-mutated WT AS was noted to have cytosolic and membrane localization,
indicated by the arrows. However, there was considerable membrane localization
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observed by the phospho-null S328A mutation (Figure 21, middle). Conversely, the
S328D AS mutation led to a largely cytosolic distribution when overexpressed (Figure
21, right). These results suggest that the phospho-null moiety of AS may localize to the
plasma membrane.

Phospho-null S328A AS is enriched in membrane fraction
In order to corroborate the observation from microscopy that S328A is associated
with the plasma membrane, we sought to determine whether different mutations at S328
affect its association with membrane components. Since membrane components are
largely insoluble, membrane protein solibilization of BAECs overexpressing WT, S328A,
or S328D AS was performed using the Mem-PER membrane protein solubilization kit
(Pierce) in order to solubilize membrane and membrane associated proteins such as AS.
As expected, non-transfected cells showed that some AS was found associated with
solubilized membrane proteins, which corroborates previous findings (Figure 22).
However, WT and S328A transfected cells showed robust detection of AS in solubilized
plasma membrane components (Figure 22). In contrast, the phospho-mimetic S328D
overexpressing cells showed very little AS associated with solubilized membrane
proteins, similar to that of non-transfected cells (Figure 22). These data are consistent
with the confocal images showing the phospho-null S328A associates with the plasma
membrane, and phospho-mimetic S328D does not.
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Total AS, but not endogenous pS328 AS, is found in the membrane enriched fraction
After observing changes in AS localization relative to the S328 mutation, the
localization of endogenously phosphorylated S328 AS was assessed. In these
experiments, we used the concanavalin A (Con A) plasma membrane enrichment
technique rather than the plasma membrane solubilization in order to demonstrate
consistency in results across different methodologies. Con A is a lectin that binds
glycosylated moieties on the plasma membrane. In this assay, biotinylated Con A is
immobilized to streptavidin coated magnetic beads followed by incubation with cell
lysate to bind plasma membranes. Beads are washed for removal of cytosolic proteins
and membrane components are displaced with use of a high sugar concentrated solution
to elute proteins of interest. Since pS1179 eNOS is known to associate with the plasma
membrane, identification of pS1179 eNOS was used as a positive control. Western of
caveolin-1 enrichment was used to show that membrane protein enrichment was
achieved. When non-treated BAECs were subjected to Con A fractionation, total AS was
found to associate with the plasma membrane, however, endogenously phosphorylated
pS328 AS was found only in the cytosol (Figure 23). These results support the previous
findings that identified overexpressed S328D AS is cytosolic in that endogenous
phosphorylation of AS at S328 was found only in the cytosolic fraction after membrane
protein enrichment.

Phospho-null and wild type AS, but not phospho-mimetic AS, associate with caveolin
Since S328 is 3 amino acids away from a putative caveolin binding motif of AS,
the association of S328A, S328D, and WT overexpressed AS with caveolin was
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determined. BAECs were transiently transfected with either construct as described above.
Lysates were then immunoprecipitated with anti- AS antibody, and non-transfected cells
were immunoprecipitated with anti-V5 antibody as negative control. Eluates from each
immunoprecipitation were then assayed for caveolin via western blot. As shown in Figure
24, immunoprecipitated WT AS and phospho-null S328A AS co-precipitated caveolin-1.
However, immunoprecipitated S328D AS, or immunoprecipitated anti-V5 in negative
control lysates, did not co-precipitate caveolin. These results suggest that nonphosphorylated S328 AS, but not phosphorylated S328 AS associates with caveolin, and
presumably the plasma membrane.

pS328 AS and eNOS co-localize in cytosol upon calcium stimulation
Since it has been established that eNOS translocates to the cytosol in response to
calcium mediated stimulation in endothelial cells, and our results indicate that AS
translocates to the cytosol as well, we sought to determine whether AS and eNOS colocalize in the cytosol as the result of calcium-mediated stimulation. BAECs were grown
on culture slides then cells were stimulated with calcium ionophore, insulin, or nothing,
then probed for pS328 AS (green) and eNOS (red) (Figure 25). Non-treated BAECs
showed some pS328 AS and eNOS co-localization (yellow) in the perinuclear region,
however, upon calcium stimulation, robust co-localization of pS328 AS and eNOS was
observed in the perinuclear region. Conversely, cells stimulated with insulin showed
eNOS strongly associated with the plasma membrane, yet little pS328 AS was localized
with eNOS or detected overall. These results suggest that calcium stimulation promotes
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eNOS and pS328 AS co-localization in the perinuclear region, and pS328 AS and eNOS
do not associate under insulin stimulation.

Total AS and eNOS associate upon insulin stimulation
From the confocal microscopy, it appeared that eNOS and pS328 associate at
basal conditions, but do not associate with insulin stimulation. Therefore, to demonstrate
a physical interaction between AS and eNOS, immunoprecipitation of eNOS was
performed with non-treated or insulin treated BAEC lysates to observe pS328 AS or nonphosphorylated AS (48 kDa) co-precipitation relative to insulin treatment. When eNOS
was immunoprecipitated, pS328 was found to co-precipitate in non-treated BAEC lysates
(Figure 26). However, when cells were treated with insulin, robust co-precipitation of
48kDa AS was found in the eNOS immunoprecipitation eluate. These results support the
observations from confocal microscopy that pS328 AS associates with eNOS under nonstimulated conditions, and that non-phosphorylated AS associates with eNOS when
stimulated with insulin.

Phospho-mimetic and phospho-null AS have same enzymatic activity as WT
In order to establish whether regulation at S328 affects enzymatic activity of AS,
S328A, S328D or WT AS constructs were overexpressed in BAECs with endogenous AS
knocked down, then NO production was assessed. S328A, S328D, and WT constructs
were designed to have silent mutations in the region that the siRNA bound, allowing only
endogenous AS to be susceptible to the siRNA. As shown in Figure 27, WT AS
overexpression effectively recovered NO production relative to AS knockdown alone.
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Additionally, overexpression of S328A and S328D AS recovered NO production in a
manner consistent with WT AS overexpression. These data suggest that regulation at
S328 does not affect enzymatic activity of AS.

Discussion
Since endothelial stimulation with factors that rely on increased intracellular
calcium lead to eNOS cytosolic translocation (14-16), we investigated whether the
calcium-dependent phosphorylation of AS at S328, positioned near a putative caveolin
binding motif, promoted a cytosolic translocation of AS as well. Using site-directed
mutagenesis to generate the phospho-null S328A and phospho-mimetic S328D AS
constructs, we identified altered localization patterns and protein-protein interactions of
AS relative to S328 mutation compared to wild type (WT) AS. We then confirmed
changes in localization predicted by S328 mutation experiments through analysis of
endogenous pS328 AS localization.

We have previously observed decreased phosphorylation at S328 of AS in
response to calcium-independent stimulation with insulin or VEGF (Part II), as well as
established a proximal relationship between enzymes in the citrulline-NO cycle (23).
Since it is well established that insulin mediates plasma membrane localization of eNOS
(17), we hypothesized that the phospho-null S328A AS may co-localize with eNOS in
response to calcium- independent stimulation of eNOS. Moreover, we suspected that a
possible role of phospho-null S328 AS may be to localize to the plasma membrane to
provide arginine recycling for plasma membrane localized eNOS. Indeed, the phospho-
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null S328A AS showed increased membrane localization via immunofluorescent
confocal microscopy relative to WT or phospho-mimetic S328D AS. Furthermore, we
showed that S328A AS protein was also enriched when plasma membrane proteins were
solubilized and assayed by western blot, indicating that the phospho-null form of AS is
associated with plasma membrane components. Consistent with this data,
immunoprecipitation of S328A, S328D, or WT showed caveolin, a plasma membrane
protein, in eluates of S328A and WT transfected cells. Furthermore, immunoprecipitation
of eNOS after insulin stimulation showed co-precipitation of the 48 kDa nonphosphorylated AS moiety that did not co-precipitate under non-stimulated conditions.
Taken together, these data suggest that the phospho-null S328 moiety of AS associates
with eNOS via protein-protein interaction with caveolin during calcium-independent
stimulation of endothelial cells.

Since phosphorylation at S328 is calcium-dependent, the identification of a
calcium sensitive regulatory mechanism proximal to a caveolin binding motif led us to
hypothesize that S328 phosphorylation may promote a cytosolic translocation of AS
similar to eNOS translocation in response to calcium. From immunofluorescent confocal
microscopy, we identified diffuse expression of phospho-mimetic S328D AS throughout
the cytosol, suggesting that S328D does not have an affinity for the plasma membrane.
Consistant with this observation, overexpressed S328D AS was not associated with
solubilized plasma membrane proteins. These results, in conjunction with the
juxtaposition of S328 to a putative caveolin binding motif of AS, led us to address the
question regarding the ability of S328D AS to interact with caveolin.
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Immunoprecipitation of overexpressed phospho-mimetic S328D AS showed that caveolin
did not co-precipitate with S328D AS, suggesting that S328 phosphorylation negatively
affects AS-caveolin interaction. These results support the idea that S328 phosphorylation
may impair AS association with the plasma membrane and thus lead to cytosolic
localization. In addition, we corroborated overexpression experiments by evaluating the
cellular distribution of endogenous pS328 AS by membrane enrichment and
immunofluorescent confocal microscopy. Similar to overexpression experiments,
endogenous pS328 AS was identified only in the cytosolic fraction after Con A plasma
membrane enrichment of BAECs. Endogenous pS328 AS also showed cytosolic
distribution AS in confocal microscopy, again agreeing with observed S328D cellular
distribution. Collectively, these data demonstrate by observation of endogenous pS328
AS and exogenous S328D in confocal microscopy and membrane fractionation, that
phosphorylation at S328 promotes cytosolic distribution of AS.

In order to visually evaluate the effect of calcium or insulin stimulation on
endogenous pS328 AS and eNOS localization, immunofluorescent confocal microscopy
with cells treated with calcium ionophore or insulin was conducted. Importantly, we
showed perinuclear co-localization of pS328 AS and eNOS increased relative to calcium
stimulation, and relatively no pS328-eNOS co-localization with insulin treatment.
Furthermore, we showed that eNOS and pS328 physically associate in that
immunoprecipitation of eNOS co-precipitated pS328 AS, thus corroborating confocal
microscopy data. These data indicate that a function of pS328 AS may be to co-localize
with cytosolic eNOS to provide site specific arginine recycling. To this end, we were
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interested in determining whether regulation at S328 affects the activity of the AS
enzyme. Transfection with WT, S328A or S328D AS, in BAECs with endogenous AS
knocked down, showed no change in NO production relative to the mutation, indicating
that modification at S328 of AS does not affect enzymatic activity. The demonstration
that S328 modification does not affect AS activity suggests that the sole function of S328
phosphorylation is to modulate AS localization. Above all, the present study suggests that
the proximal relationship of AS and eNOS is a key factor in maintaining the citrullineNO cycle in endothelial cells.
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Figure 21. Phospho-mimetic S328D mutation promotes cytosolic distribution of AS.
BAECs were transiently transfected with either wild type (WT, left), phospho-null
(S328A, middle) or phospho-mimetic (S328D, right) AS. Immunofluorescence was
performed with mouse anti-V5 primary antibody and goat anti-mouse secondary antibody
conjugated to alexa-488. Images were obtained with an Olympus FV1000 MPE
multiphoton laser scanning microscope at 60X with oil immersion. Arrows indicate areas
of acute V5 detection. Images are representative of 3 separate experiments.
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Figure 22. Phospho-mimetic S328D mutation diminishes AS detection in solubilized
BAEC membrane proteins. BAECs were either not transfected (first lane), or transiently
transfected with wild type AS (WT, second lane), phospho-null S328A (third lane, or
phospho-mimetic S328D (fourth lane) mutated AS. Cells were lysed with RIPA then
insoluble material was retrieved and washed. Insoluble membrane components were
solubilized and analyzed by western blot. Results are representative of 2 experiments.
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Figure 23. Endogenous phospho-null S328 AS, but not phospho-S328 AS, is found in the
membrane enriched fraction of BAEC lysates. BAECs were grown to confluence then
lysed by sonication. Magnetic beads conjugated to the lectin Con A were used to
immobilize glycosylated membrane components followed by wash and elution of
membrane and membrane associated components. Analysis of elutions was performed by
western blot. eNOS pS1179 was used as positive control for enrichment of membrane
associated proteins, and caveolin-1 detection was used to confirm of membrane
enrichment. Results are representative of 2 experiments.
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Figure 24. Caveolin-1 co-precipitated with WT and phospho-null S328A overexpressed
AS, but not S328D overexpressed AS. BAECs were transiently transfected with either
wild type (WT), phospho-null (S328A) or phospho-mimetic (S328D) AS, lysed with lowdetergent lysis buffer, then immunoprecipitated with anti-AS antibody.
Immunoprecipitation with anti-V5 antibody (used as non-specific IgG) was performed
with non-transfected cell lysates as negative control. Eluates were analyzed for presence
of caveolin-1 by western blot. Results are representative of 1 experiment.

134

Figure 25. Calcium stimulation of BAECs promotes cytosolic co-localization of
endogenous phospho-S328 AS and eNOS. BAECs were grown on culture slides then
treated with either nothing (left), calcium ionophore (middle), or insulin (right). Cells
were analyzed by immunofluorescence with primary antibodies rabbit anti-phospho-S328
and mouse anti-eNOS, and secondary antibodies goat anti-rabbit alexa-488 and goat antimouse alexa-594. Green represents phospho-S328 detection, red eNOS detection, and
yellow denotes co-localization. Arrows indicate co-localization in non-treated cells and
calcium ionophore cells. In insulin treated cells, bottom arrow points to eNOS plasma
membrane localization, upper arrow points to absence of co-localization. Results are
representative of 3 experiments.
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Figure 26. Insulin promotes phospho-null S328 AS association with eNOS. BAECs were
grown to confluence, serum starved overnight, then treated with or without insulin.
Lysates were immunoprecipitated with anti-eNOS antibody then eluates were analyzed
for pS328 or AS co-precipitation by western blot. Results are representative of 2
experiments.
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Figure 27. AS activity is not affected by phospho-null or phospho-mimetic mutation of
S328. Endogenous AS was knocked down in BAECs, then were transiently transfected
with either WT, phospho-null S328A, or phospho-mimetic S328D AS constructs.
Extracellular NO production was assessed with the DAN assay. Values are plotted as
pMol nitrite per microgram protein. Data represents the results from 4 experiments.
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DISCUSSION

Endothelial function is defined by the ability to efficiently produce nitric oxide
(NO). NO homeostasis is critical in preventing thrombus formation, overexpression of
endothelial adhesion molecules, and promoting vasodilation. The production of
endothelial NO occurs through the citrulline-NO cycle that involves the catalysis by three
enzymes: argininosuccinate synthase (AS), argininosuccinate lyase (AL), and endothelial
nitric oxide synthase (eNOS). AS and AL recycle eNOS derived citrulline back to
arginine to serve as eNOS substrate for the production of NO. Importantly, AS catalyzes
the rate-limiting step in the arginine recycling associated with NO production.
Furthermore, inhibiting AS expression and preventing endothelial cells from recycling
arginine from citrulline leads to inhibition of NO production and endothelial apoptosis.
Therefore, arginine recycling is a critical aspect of the citrulline-NO cycle, and the
regulation of eNOS and AS is essential in maintaining endothelial function. The work
described here is the result of investigating the role that acute regulation of AS by
phosphorylation at serine 328 (S328) plays in the citrulline-NO cycle.

Several mechanisms describing the regulation of eNOS activity have been
elucidated, including phosphorylation, lipid modification, and protein-protein
interactions. However, much less has been established relating to the regulation of AS in
endothelial cells. What has been demonstrated is that AS is co-regulated with eNOS at
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the level of transcription in response to several physiological factors including shear
stress (1), PPARγ agonist troglitazone, insulin (2), and TNFα (3). Furthermore, it has
been demonstrated that AS and eNOS have a proximal relationship at caveolae in
endothelial cells (4). Since NO is a readily diffusible free radical that cannot be
intracellularly stored, the spatial and temporal regulation of NO production is imperative
in order to mediate endothelial function. Given that AS and eNOS are co-regulated
transcriptionally and have been demonstrated to have a proximal relationship, it is logical
to hypothesize that AS is regulated spatially and temporally with eNOS in order to meet
the cellular demands for NO. Since phosphorylation is a type of post-translational
modification associated with mediating acute changes in subcellular localization and
activity, we pursued the hypothesis that AS is phosphorylated, and AS phosphorylation
plays a role in NO production.

In order to evaluate the possibility that AS and eNOS are co-regulated by
phosphorylation, we first demonstrated that AS exists as a phospho-protein in endothelial
cells (5). Subsequently, we analyzed the AS protein by mass spectrometry to identify
potential phosphorylation sites. In order to identify phosphorylation sites associated with
a response to physiological cues, AS was purified from BAECs treated with factors
known to increase phosphorylation of eNOS, such as bradykinin or okadaic acid
(phosphatase inhibitor). From this analysis, we identified the candidate phosphorylation
site serine 328 (S328). We then analyzed the impact of mutating the site to phospho-null
(S328A) or phospho-mimetic (S328D) on calcium ionophore stimulated NO production
when constructs were overexpressed in BAECs. Results indicated that WT and phospho-
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mimetic S328D constructs supported calcium stimulated NO production, while the
phospho-null S328A construct yielded significantly less NO production. These results
suggested that phosphorylation at S328 may play a role in supporting NO production. As
a result, we subsequently generated a phospho-S328 specific antibody for further
characterization of phosphorylation at S328.

In order to understand the conditions associated with AS phosphorylation at S328,
we treated cultured endothelial cells with several physiological factors known to
modulate NO production. Several types of stimulators of NO production (acetylcholine,
calcium ionophore, bradykinin, insulin, VEGF, lysophosphatidic acid, sodium vanadate,
Nor-NOHA, and estradiol) were used, in addition to NO production inhibitors (free fatty
acid, TNFα, homocysteine, and ADMA). The results from these experiments showed that
AS S328 and eNOS S1179 (activates eNOS) were coordinately regulated in response to 9
out of 13 treatments. In addition, the factors that stimulate eNOS activity in a calcium
dependent manner promoted S328 phosphorylation, while Akt mediated eNOS
stimulation (calcium-independent eNOS activation) led to a decrease in S328
phosphorylation. Similarly, factors that lead to a decrease in intracellular calcium led to
diminished phosphorylation of AS at S328. From these experiments, we concluded that
S328 phosphorylation was co-regulated with eNOS in response to factors that alter
intracellular calcium.

After establishing that phosphorylation at S328 was co-regulated with eNOS
S1179 under certain conditions, we then hypothesized that the AS phosphorylation at
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S328 was calcium-dependent, and that a calcium dependent kinase may phosphorylated
AS. Results showed that calcium and thapsigargin stimulation of cultured endothelial
cells led to increased phosphorylation at S328, while chelating intracellular calcium with
BAPTA-AM completely abolished S328 phosphorylation of AS. Furthermore, kinase
inhibition and gene knockdown studies suggested that S328 is phosphorylated by the
calcium-dependent kinase PKCα. Since PKCα is not activated by insulin or VEGF
signaling, this agrees with previous data indicating that S328 phosphorylation is
associated with calcium dependent stimulation of eNOS. We concluded from this work
that AS phosphorylation at S328 is indeed calcium-dependent and is mediated by PKCα.

After establishing the circumstances that promote S328 phosphorylation of AS,
we were interested in determining the function of pS328 AS. Since eNOS translocates to
the cytosol upon calcium stimulation, we hypothesized that a potential function of
phosphorylation at S328 occuring in a calcium-dependent manner may be to translocate
AS from plasma membrane to the cytosol with eNOS. Further support for this hypothesis
was based on the fact that activated PKCα is associated with the plasma membrane,
therefore S328 phosphorylation may occur at the plasma membrane to initiate a
translocation event. In support of this hypothesis, a putative caveolin binding motif, 3
amino acids away from S328, was identified in the AS protein sequence. Therefore, we
performed site directed mutagenesis at S328 to observe changes in localization by
immunofluorescence and membrane fractionation. In addition, we immunoprecipitated
mutated AS and analyzed co-precipitates for the membrane associated protein caveolin-1,
which was predicted to associate with AS near S328. Results showed that the phospho-
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mimetic mutation at S328 (S328D) promoted cytosolic localization and absence of
caveolin-1 interaction, while the phospho-null mutation (S328A) showed membrane
localization and caveolin-1 interaction. Furthermore, we showed co-precipitation of nonphosphorylated AS with eNOS when BAECs were treated with insulin. However, pS328
AS, but not non-phosphorylated AS, associated with eNOS when cells were untreated.
These data suggest that 1) S328 phosphorylation negatively regulates AS interaction with
caveolin, 2) insulin promotes AS association with plasma membrane localized eNOS, 3)
calcium promotes AS association with cytosolic localized eNOS. Furthermore, since the
activity of AS was not affected by S328 mutation, these results indicate that the role of
phosphorylation at S328 is primarily to modulate the localization of AS to maintain
proximity to cytosolic eNOS in response to calcium.

Regardless of the manner in which eNOS is stimulated relative to calcium, the
bulk intraendothelial arginine concentration at any given point far exceeds the eNOS
Michealis-Menton constant (Km), yet eNOS is rarely saturated with substrate. This
phenomenon is referred to as the "arginine paradox", and several potential mechanisms
have been offered to explain the basis for this contrariety. For example, experiments
performed by McDonald and others suggested that the neutral amino acid transporter,
CAT 1, channels exogenous arginine to eNOS since inhibition of eNOS association with
CAT 1 attenuated arginine uptake by endothelial cells (6). However, Venema and others
showed that inhibition of arginine uptake by saturating the transporter with lysine did not
decrease the degree of NO output (7). These findings suggested that the observed
increase in NO is not dependent on arginine uptake through CAT1, but rather the protein-
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protein interaction of eNOS with the transporter. These experiments raise doubt relating
to the CAT 1 channeling of arginine to eNOS, but do not address the likely source of
arginine for eNOS. The data presented in this report suggested that the maintenance of
sequestered arginine pools by argininosuccinate synthase in the proximity of eNOS is
required to maintain NO homeostasis. Since NO signaling in endothelial cells and other
tissue types (neurons, macrophage, etc) is critical for survival, a localized
microenvironment of accessible arginine by eNOS is essential, since it is well established
that the arginine consuming enzyme arginase competes with eNOS for substrate. That
being the case, the presence of proximal relationship between eNOS and arginine
recycling from citrulline ensures that a constant supply of arginine is available to eNOS
in order to maintain cell viability and function. As a result, a basal level of intracellular
and/or extracellular NO production can be maintained despite conditions of diminished
substrate availability by arginase. For these reasons, a logical explanation to the arginine
paradox is that the co-regulation of AS and eNOS localization supports the maintenance
of the eNOS arginine microenvironment in the endothelial response to factors that
promote changes in eNOS subcellular distribution or substrate competition.

Surprisingly, the implications of cytosolic eNOS localization and intracellular NO
production have not been fully defined. What has been defined is that intra-endothelial
NO production is required to S-nitrosylate cysteine 163 of caspase 3, thereby inhibiting
the caspase cascade that leads to endothelial cell apoptosis. In addition, ER localized
eNOS has been suggested to play a role in S-nitrosylation of other proteins. However, Snitrosylation, in most circumstances, is considered a non-specific cellular response to
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oxidative stress rather than specific alteration of particular pathways, as is the case with
phosphorylation. For example, increased oxidative stress and reactive nitrogen species
leads to S-nitrosylation of cellular proteins, which allows them to adapt to the altered
redox state (i.e. prevents protein oxidation or degradation) (8). It is not likely that the sole
purpose of cytosolic NO production is to mediate redox adaptation, since bradykinin, a
physiological stimulator of NO production and vasodilation, does not promote oxidative
stress (9), yet has been shown to stimulate eNOS cytosolic translocation (10, 11).
Furthermore, the measurement of intracellular NO and extracellular NO is rarely
performed in the same experiment, however, when the two methods are used, the two sets
of data seldom agree. For example, it is often reported that intracellular localized eNOS
(i.e. myristoylation mutant G2A eNOS) is less active than wild type eNOS, however, the
method to detect NO production in these experiments utilized extracellular culture media
and did not account for intracellular NO production (12). If the cytosolic eNOS that
generates intracellular NO is generated and consumed by the endothelial cell, it would
likely not be detected in extracellular culture media. Indeed, Church et al showed that the
eNOS myristoylation mutant generated significantly less NO than WT eNOS when NO
production was assayed from culture media, however, upon cellular disruption, the eNOS
myristoylation mutant was found to actually generate more NO than WT (13). This
suggests that the myristoylation mutant is active, but its product is not detected as
efficiently in culture media. This further supports the idea that intracellular eNOS
generates NO that does not reach outside the cell. These observations may lead one to
surmise that intracellular NO production may serve a role specific to endothelial biology
in addition to the other well characterized NO signaling mechanisms.
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Relative to these details, the observation that impaired intracellular NO
production results in apoptosis implies that maintaining intracellular NO levels is critical
to endothelial function. Our results here suggested that AS co-localizes with eNOS at the
plasma membrane in response to insulin, whereas calcium stimulation led to AS colocalization with eNOS in the cytosol, thereby setting the stage for multiple sites of
citrulline-NO cycle activity. Given these points, it is tempting to hypothesize that
cytosolic co-localization of AS and eNOS promotes intracellular NO production, and
therefore plays a significant role in intra-endothelial signaling and function, beyond what
is known relative to nitrosylation or prevention of apoptosis. Further investigation
relating to additional functions of the citrulline-NO cycle regarding intracellular NO
production in endothelial function may give insight relative to pathologies associated
with the vascular endothelium.
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APPENDIX:
INSULIN TRANSCRIPTIONALLY REGULATES ARGININOSUCCINATE
SYNTHASE TO MAINTAIN VASCULAR ENDOTHELIAL FUNCTION2

Summary
Diminished vascular endothelial cell nitric oxide (NO) production is a major
factor in the complex pathogenesis of diabetes mellitus. In this report, we demonstrate
that insulin not only maintains endothelial NO production through regulation of
endothelial nitric oxide synthase (eNOS), but also via the regulation of argininosuccinate
synthase (AS), which is the rate-limiting step of the citrulline-NO cycle. Using serum
starved, cultured vascular endothelial cells, we show that insulin up-regulates AS and
eNOS transcription to support NO production. Moreover, we show that insulin enhances
NO production in response to physiological cues such as bradykinin. To translate these
results to an in vivo model, we show that AS transcription is diminished in coronary
endothelial cells isolated from rats with streptozotocin (STZ) -induced diabetes.
Importantly, we demonstrate restoration of AS and eNOS transcription by insulin
treatment in STZ-diabetic rats, and show that this restoration was accompanied by
improved endothelial function as measured by endothelium-dependent vasorelaxation.

2

Published in Biochemical and Biophysical Research Communications March, 2012. Keywords: AS,
insulin, streptozotocin, eNOS, vasorelaxation
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Overall, this report demonstrates, both in cell culture and whole animal studies, that
insulin maintains vascular function, in part, through the maintenance of AS transcription,
thus ensuring an adequate supply of arginine to maintain vascular endothelial response to
physiological cues.

Introduction
The hallmark of endothelial dysfunction is the inability of endothelial cells to
release nitric oxide (NO) in response to physiological cues that promote vasodilation (1).
NO production in endothelial cells is supported by the citrulline-NO cycle which is
comprised of three enzymes: the arginine recycling enzymes argininosuccinate synthase
(AS) and argininosuccinate lyase (AL), and endothelial NO synthase (eNOS) (2).
Various studies, both in vitro and in vivo, have demonstrated that arginine recycling is
required for the physiologically regulated production of endothelial NO (3-6).

Endothelial NO is a readily diffusible free radical that stimulates soluble guanylyl
cyclase in smooth muscle cells to regulate smooth muscle relaxation and blood vessel
dilation. Consequently, impaired production of NO by endothelial cells contributes to
hypertension (1). Since endothelial NO plays a critical physiological role in controlling
vasodilation, the regulation of eNOS has been extensively investigated to better
understand the mechanisms which regulate NO production. Several physiological
factors, such as acetylcholine, bradykinin, and insulin are known to regulate eNOS to
increase NO production by vascular tissues. Acetylcholine and bradykinin are acute
regulators recognized to promote NO production by increasing eNOS activity through
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phosphorylation at serine-1177 (bovine S1179) (7, 8). Insulin is likewise known to
stimulate eNOS activity to promote NO production through phosphorylation; however,
insulin has also been acknowledged to support NO production via maintenance of eNOS
transcription (9, 10).

Importantly, it is also known that the loss of insulin sensitivity, which underlies
the cause of type 2 diabetes, results in serious vascular complications, including
hypertension (11). Because of this, the vasodilatory effects of insulin have been
extensively studied and shown to be mediated essentially through NO signaling. For
example, in type 2 diabetes where insulin signaling is impaired (12-14), treatment with
sodium nitroprusside (SNP), an NO donor, improved vasodilation (15). The association
of endothelial dysfunction with type 2 diabetes (16, 17) is further supported by reports
showing that therapeutic interventions used to alleviate the insulin resistance also
ameliorated endothelial dysfunction (18, 19).

Unlike eNOS, however, there is a limited understanding of the regulation of AS,
which catalyzes the rate-limiting step in the citrulline-NO cycle in endothelial cells. The
current literature suggests that AS mRNA levels appear to be coordinately regulated by
physiological factors that regulate eNOS to affect endothelial NO production (20, 21).
For example, the pro-inflammatory cytokine TNFα has been shown to coordinately
decrease eNOS and AS transcription in endothelial cells (5), while the PPARγ agonist
troglitazone, as well as sheer-stress, have been shown to coordinately increase eNOS and
AS transcription (22). In the work presented here, we investigated how insulin mediates
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its effects on the citrulline-NO cycle, not only by affecting eNOS expression, but also AS
expression in order to ensure that the levels of available arginine are sufficient to support
eNOS-catalyzed NO production. To examine this question, we investigated whether
insulin supports the expression of AS mRNA in vascular endothelial cells; and if so, if
changes in AS mRNA levels mediated by insulin coordinate with eNOS mRNA levels.
Two systems were used to investigate this question; cultured bovine aortic vascular
endothelial cells and coronary endothelial cells isolated from streptozotocin-induced type
1 diabetic rats.

Experimental procedures
Cell culture
Bovine aortic endothelial cells (BAEC) were cultured in complete DMEM (1 g/L
glucose, Mediatech) containing 10% fetal bovine serum (Hyclone Laboratories), 100
units/ml penicillin and 100 g/ml streptomycin (Mediatech) at 37C and 5% CO2.

Rat STZ-diabetic in vivo model
Insulin-dependent diabetes was induced in male Sprague-Dawley rats
(approximately 300 grams) by injecting 65 mg/kg streptozotocin (STZ) (Sigma, in 0.1 M
citrate buffer, pH 4.5) into the peritoneal cavity. Control rats received vehicle injection
only. Three experimental groups of animals were followed for 21 days: (i) STZ-diabetic
rats (STZ, n = 8); (ii) age-matched control non-diabetic rats treated with vehicle only
(Controls, n = 16), and (iii) STZ-diabetic rats receiving subcutaneously delivered insulin
(STZ + INS, n = 4, for each dose). Insulin was delivered via a slow release pellet
(LinPlant) implanted under the dorsal skin of the neck according to the manufacturer’s
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(LinShin Canada) instructions. The size of the pellet was chosen to deliver consistent
daily doses of insulin from 1-5 IU/day, allowing maintainance of normo-glycemia or
mild to moderate hyperglycemia, if desired, in the animals. The pellets provided insulin
delivery for up to 56 days.

Non-fasting blood glucose concentration and body weight of all animals were
measured weekly and when animals were sacrificed. Blood glucose was measured using
a One-Touch Ultra glucose meter (LifeScan). At 21 days, animals were euthanized and
the hearts removed for isolation of coronary endothelial cells (CEC) as described by
Zuidema et al (23). Briefly, ventricular tissue in 20mM HEPES was digested with
Liberase Blendzyme 3 (final 0.02-0.07 mg/ml; Roche) and CEC were isolated using
biotinylated PECAM-1antibody (Sertec) and streptavidin-coated M280 magnetic beads
(Invitrogen). Endothelial cells bound to beads were isolated using a magnetic stand to
collect CEC. CEC for total RNA isolation were frozen in RNAlater (Applied
Biosystems).

NO determinations
Confluent BAECs were serum starved for 16 hr in DMEM without phenol red,
and in the presence of 0.1% BSA (Fraction V, Sigma)then treated with 10 nM insulin, 10
µM bradykinin, both or neither for 4 hours. The total nitrite from cell culture media was
measured using the 2,3-diaminonaphthalene (DAN) assay and BMG Fluostar Galaxy
spectrofluorometer using an excitation wavelength of 360 nm and emission wavelength
of 405 nm. (24).
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Western blot analysis
BAECs were serum starved as described above followed by treatment with 10 nM
insulin for 2 hr and then harvested and lysed by scraping in RIPA buffer (1% NP-40,
0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, 1X protease inhibitors
(Calbiochem) in PBS). Protein concentrations were determined by BCA assay (Pierce)
and equal amounts of protein were resolved on 4-15% Tris-HCl SDS-polyacrylamide
gels (Bio-Rad) and blotted onto Immobilon PVDF (Millipore) for immunoblotting.
Primary antibodies used include anti-AS and anti-eNOS (BD Transduction Labs) and
anti-GAPDH (Novus Biologicals). Secondary antibodies used were peroxidaseconjugated goat anti-mouse or anti-rabbit IgG (Jackson ImmunoResearch Labs). Blots
were visualized by chemiluminescence using ECL reagent (Pierce) and exposed to film.

RNA isolation and quantitative RT-PCR
To measure steady state RNA expression of AS and eNOS, total RNA from
cultured BAEC and isolated rat CEC was isolated using Tri Reagent according to the
manufacturer’s recommendations (MRC) and as described previously (25). RNA was
treated with DNase (Ambion) and quantitated prior to reverse transcription with the High
Capacity cDNA kit (Applied Biosystems) according to the manufacturer’s instructions.
Quantitative RT-PCR (qRT-PCR) was performed using the following probe/primer sets:
bovine AS sense (5´-TCAGCAAGGAGTTTGTGGAGGAGT-3´) AS antisense (5´ACACATACTTGGCTCCTTCTCGCT-3´) AS probe (5´-FAM
ATCCAGTCCAGCGCACTGTACCAGGABHQ-3´); bovine eNOS sense (5´-
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TACATGAGCACGGAGATTGG-3´) and eNOS antisense (5´AGCACAGCCAGGTTGATCTC-3´) detected with sybr green; and GAPDH sense (5´CATGTTTGTGATGGGCGTGAACCA-3´), GAPDH antisense (5´TGATGGCGTGGACAGTGGTCATAA-3´), GAPDH probe (5´-ROXN
ATTGTCAGCAATGCCTCCTGCACCACCAABHQ-3´). Data for bovine gene
expression levels was normalized to GAPDH. Rat mRNA levels were detected with the
following Taqman Gene Expression Assays (Applied Biosystems) AS: Ass1
argininosuccinate synthetase 1, Rn00565808_g1; eNOS: Nos3 NO synthase 3,
Rn02132634_s1; Rplp2: ribosomal protein, large P2, Rn01479927_g1. Data for rat gene
expression levels was normalized to Rplp2.

Aortic ring preparation and vascular reactivity measurement
Endothelium-dependent vascular reactivity was assessed as previously described
(26). Briefly, abdominal aortic rings were fixed on two stainless steel wires, one attached
to a force transducer and the other attached to a micrometer. The rings were then lowered
into a bath containing Krebs bicarbonate buffer, equilibrated for 1.5 hours, followed by
pre-constriction with norepinephrine (10-6 mol/L), and the concentration-response
relationships to acetylcholine (Ach, 10-10~10-6 mol/L) were determined by cumulative
addition of Ach in half-log increments directly to the bath. In all rings, NO-mediated
relaxation was verified at the end of the experiment using 100 mmol/L sodium
nitroprusside (SNP), a spontaneous NO donor used to assess endothelium-independent
relaxation of aortic rings.
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The contraction tension was recorded and vasorelaxation in response to Ach or SNP was
calculated as percent reduction from norepinephrine-induced tension.

Statistical analysis
All in vitro data were from at least three independent experiments. Results were
expressed as the mean +/- standard error. The student’s t-test was used to note statistical
significance at p < 0.05 between means of treated and control groups.

Results
Insulin treatment promotes AS and eNOS transcription to support NO production
Since the expression of AS is necessary to support endothelial NO production (6,
27-29), we investigated whether the effects of insulin on vascular endothelial NO
production may be mediated through AS, or whether the increase in NO production was
simply due to established effects on eNOS activation (30-32). To examine changes in AS
transcription that may result from insulin treatment, BAECs were grown to confluence
and then serum starved for 16 hours before treatment with insulin for 2 hours. RNA was
prepared and quantitated by qRT-PCR, and as shown in Figure A1A, there was almost a
2-fold increase in AS mRNA observed after treatment with 10 nM insulin. Similarly,
eNOS mRNA levels increased 1.5-fold (near significance) in response to insulin
treatment, and these results with eNOS were comparable to reported values (33).

With cultured endothelial cells, there was sufficient sample to verify whether
mRNA levels corresponded to protein levels. Protein levels of AS and eNOS were
determined by western blotting and, as shown in Figure A1B & A1C, insulin treatment
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resulted in an increase in AS and eNOS protein that closely correlated with the
corresponding mRNA changes. AS and eNOS expression increased 2.2-fold and 2.5-fold,
respectively, as shown in Figure A2B. These results demonstrated that insulin did indeed
promote an increase in AS as well as eNOS expression.

To show that up-regulation of AS and eNOS expression by insulin corresponded
to enhanced production of NO, cultured endothelial cells were treated with insulin under
basal and stimulatory conditions. BAEC were serum starved for 16 hours and treated with
or without insulin (10 nM) for 4 hours to measure the effect of insulin on basal NO
levels. For stimulatory conditions, BAEC were again serum starved for 16 hours, and
then treated with 10 µM bradykinin, with or without insulin (10 nM), for 4 hours. From
both determinations, culture media was collected and nitrite, a stable metabolite of NO,
was measured using the DAN assay. As shown in Figure A2, no significant change in
NO production was observed with treatment of insulin alone. However, under the
stimulatory conditions of 10 µM bradykinin, insulin enhanced the levels of NO produced
approximately 30% compared to cells treated with bradykinin alone.

Insulin restores AS expression in the streptozotocin-induced diabetic rat
To ensure that the insulin effects observed in cultured endothelial cells translate to
vascular endothelial cells from whole animals, we investigated the effects of insulin on
AS expression in the coronary endothelial cells isolated from STZ -treated diabetic rats.
The STZ-diabetic rat is a well-characterized animal model of type 1 diabetes mellitus for
metabolic studies (34, 35) and for evaluation of vascular function (20, 36), allowing us to
address 1) whether treatment with insulin in STZ-induced diabetic rats restores AS
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expression, and 2) whether insulin restoration of AS expression restores endothelial
function.

Because STZ selectively destroys insulin-producing beta cells of the pancreas
(37), the effects of STZ treatment are to generate an animal which is insulin-dependent.
This type 1 diabetes was confirmed in each animal by measuring serum glucose levels
after treatment. Nonfasting hyperglycemia in the STZ-treated rats averaged 586.3 mg/dL
blood glucose compared to 140.4 mg/dL blood glucose for the untreated, normal animals.
Correspondingly, the hyperglycemia in the STZ-treated rats decreased with increasing
doses of insulin that followed STZ treatment. For the ½ implant (25% normal insulin),
the average level in blood glucose was found to average 462.8 mg/dL, a 21% reduction in
blood glucose relative to STZ alone. For the 1 implant (50% normal insulin) blood
glucose was reduced, on average, to 315.6 mg/dL for approximately 46% reduction in
blood glucose; and for the 2 implants (100% normal insulin) the average blood glucose
was found to be slightly below the values seen in the normal rats, at 124.5 mg/dL (78%
reduction in blood glucose).

As shown in Figure A3, qRT-PCR on the RNA from isolated coronary endothelial
cells demonstrated a 50% decrease in AS mRNA levels in the STZ induced diabetic rat
relative to control animals. A similar decrease, by approximately 20% in eNOS mRNA
levels, was observed to result from STZ-treatment which was comparable with reported
literature values (20). Importantly, treatment with insulin was shown to restore both AS
and eNOS transcription in a dose-dependent fashion, consistent with results from cultured
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endothelial cells where serum starved levels of AS and eNOS mRNAs were restored by
treatment with insulin (Figure A1).

Insulin restores acetycholine induced, NO mediated relaxation in vascular rings from
streptozotocin induced diabetic rats
To demonstrate that reestablishment of AS and eNOS transcription relates to the
physiological recovery of endothelial function, vasodilatory studies were carried out on
isolated aortic rings from the STZ-treated rats. Not surprisingly, NO-dependent,
acetylcholine-stimulated vaso-relaxation was shown to be reduced in aortic rings taken
from STZ-induced diabetic rats compared to those isolated from untreated animals
(Figure A4). Relaxation values (% of maximal non-endothelium-mediated relaxation by
SNP) decreased from 61.21 ± 1.62% in the normal animals to 45.31 ± 3.97% in the STZdiabetic animals. However, aortic vessel reactivity was shown to recover in rats treated
with insulin implants as demonstrated by relaxation values of 54.03 ± 2.41% for ½
insulin implant, 70.53 ± 1.58% for 1 insulin implant, and 60.86 ± 2.65% for 2 insulin
implants. The 1 insulin implant level actually improved vessel function to a greater extent
than that observed in normal animals, consistent with its reduction in blood glucose.

Discussion
Impairment of endothelial NO production plays a pivotal role in the pathogenesis
of diabetes, compromising endothelial cell regulation of vascular function and
homeostasis (38). Therefore, deciphering the molecular mechanisms involved in the
constitutive and stimulated production of NO by vascular endothelial cells is critical to
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understanding how physiological cues mediate their cardiovascular protective effects,
thereby maintaining endothelial function, and how risk factors mediate their deleterious
effects resulting in endothelial dysfunction.

In this study, the enhancement of AS expression by insulin in BAECs was shown
to correspond to a similarly enhanced expression of eNOS, as well as to an augmented
response to bradykinin, evidenced by increased NO production relative to bradykinin
treatment alone. The fact that the response to NO stimulators, such a bradykinin, was
enhanced by insulin suggests that one action of insulin may be to poise the endothelium
to more effectively respond to physiological cues by promoting both AS and eNOS
expression. This is important since the coordinate expression of AS is necessary to
maintain an adequate source of arginine to support endothelial NO production (6). If
arginine availability is limited under conditions of no or limited insulin sensitivity, this
could lead to enzymatic uncoupling of eNOS with subsequent production of reactive
oxygen species (39).

Furthermore, using the STZ-treated diabetic rat, we showed that the absence of
insulin resulted in diminished expression of AS mRNA, as well as eNOS mRNA; the
latter having been well-established as important to insulin cardioprotective effects (3032). The loss of AS expression in coronary endothelial cells from STZ-treated diabetic
rats suggested that insulin signaling is required to maintain a functional citrulline-NO
cycle. Also noted was that aggressive insulin therapy with regards to the STZ-treated
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diabetic rats resulted in an increased expression of both eNOS and AS mRNA over that
of the control with a matching improvement in vascular function.

In summary, this examination of insulin regulation of endothelial AS transcription
provides an additional level of support for the physiological significance of AS in
vascular endothelial NO production. These results suggest that insulin preserves optimal
endothelial function by maintaining the appropriate expression of the major enzymatic
constituents of the citrulline-NO cycle.
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Figure A1. Quantitation of eNOS and AS expression in cultured cells by qRT-PCR and
western blotting. Confluent BAEC were serum starved for 16 hr and treated with 10 nM
insulin for 2 hours. Control cells were untreated. (A) Total RNA, isolated from treated
and control BAEC, was reverse transcribed and AS and eNOS mRNA levels were
measured relative to GAPDH by qRT-PCR. (B) BAEC were lysed with RIPA buffer,
equal amounts of protein were separated by SDS PAGE, and standard western blotting
was performed using anti-AS, anti-eNOS, and anti-GAPDH antibodies. (C) Quantitation
of the western blots relative to GAPDH expression respectively. (* p<0.05, ‡p<0.01)
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Figure A2. Measurement of NO production by stimulated BAEC. Confluent BAEC were
serum starved 16 hr and NO production was stimulated by 10 µM bradykinin in the
absence (BK) or presence (BK + INS) of 10 nM insulin for 4 hr. NO produced was
compared to insulin alone (INS) and untreated BAEC (control). Total nitrite from cell
culture media was measured using the 2,3-diaminonaphthalene (DAN) assay. Nitrite
levels were normalized to total protein and reported as relative change from non-treated
(control). (*p<0.05)

167

Figure A3. Quantitation of eNOS and AS mRNA expression in streptozotocin-induced
diabetic rats by qRT- PCR. Streptozotocin-induced diabetic rats were compared to
normal rats relative to insulin induced expression of AS and eNOS. Diabetic rats were
randomly divided into four groups (n=4 per group). Three groups of diabetic rats had
slow-release insulin pellets implanted under the dorsal skin of the neck at a dosage of
25% normal insulin (1/2 implant), 50% normal insulin (1 implant), and 100% normal
insulin (2 implant) for 21 days. One group of diabetic rats received no implant (STZ).
Non-diabetic (Normal) animals also received no implant. Total CEC RNA was reverse
transcribed and AS and eNOS mRNA levels were quantitated relative to ribosomal
protein, large P2 (RPLP2). (*p<0.05 compared to control, ‡p<0.05 compared to STZ
alone)
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Figure A4. Endothelium-dependent relaxation assessment of vascular rings isolated from
treated streptozotocin-induced diabetic rats. Rats were treated as described in Figure 3.
At 21 days, animals were euthanized and segments of abdominal aorta were dissected for
vessel reactivity studies. Aortic rings were pre-constricted with norepinephrine and aortic
vessel reactivity was measured in the presence of increasing concentrations of
acetylcholine (10-10-10-6 M).
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